Document:

EX-10.1

 EXHIBIT 10.1 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”) is dated as of June 2, 2016 by and among Pieris
Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the
“Purchasers”). 
 RECITALS 

A. The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and
Exchange Commission (the “Commission”) under the Securities Act. 
 B. Each Purchaser, severally and not jointly,
wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate number of shares of common stock, par value $0.001 per share (the “Common Stock”), of the
Company, set forth below such Purchaser’s name on the signature page of this Agreement (which aggregate amount for all Purchasers together shall be three million two hundred twenty five thousand eight hundred four (3,225,804) shares of
Common Stock (the “Common Shares”)), (ii) that aggregate number of shares of Series A Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”), of the Company, if any, set
forth below such Purchaser’s name on the signature page of this Agreement (which aggregate amount for all Purchasers together shall be four thousand nine hundred sixty three (4,963) shares of Preferred Stock (the “Preferred
Shares” and, together with the Common Shares shall be collectively referred to herein as the “Shares”)) (the shares of Common Stock issuable upon conversion of the Preferred Stock collectively are referred to
herein as the “Underlying Shares”) and (iii) warrants, in substantially the form attached hereto as Exhibit A (the “Warrants”), to acquire up to that number of additional shares of Common
Stock equal to 60% of the number of Shares purchased by such Purchaser (for such purpose, counting the Preferred Shares with reference to the number of Underlying Shares), rounded up to the nearest whole share (the shares of Common Stock issuable
upon exercise of or otherwise pursuant to the Warrants collectively are referred to herein as the “Warrant Shares”). 

C. The Shares, the Underlying Shares, the Warrants and the Warrant Shares collectively are referred to herein as the
“Securities”. 
 D. The Company has engaged Cowen and Company, LLC to act as lead placement agent (the
“Placement Agent”) and Oppenheimer & Co. Inc., and Trout Capital LLC as co-placement agents (the “Co-Placement Agents”) for the offering of the Shares and Warrants on a “best
efforts” basis. 
 E. Contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and
delivering a Registration Rights Agreement, substantially in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which, among other things, the Company will agree to provide certain
registration rights with respect to the Shares and the Warrant Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws. 

 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agree as follows: 

ARTICLE I 
 DEFINITIONS 

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
shall have the meanings indicated in this Section 1.1: 
 “Accredited Investor Questionnaire” means the
Accredited Investor Questionnaire set forth as Exhibit C-1 hereto. 
 “Action” means any action, suit,
inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation pending or, to the Company’s Knowledge, threatened against the Company or any of their respective properties or any officer,
director or employee of the Company acting in his or her capacity as an officer, director or employee before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency, regulatory authority, stock
market, stock exchange or trading facility. 
 “Affiliate” means, with respect to any Person, any other Person that,
directly or indirectly through one or more intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. With respect to a Purchaser, any
investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 

“Agreement” has the meaning set forth in the Preamble. 

“Board of Directors” means the board of directors of the Company. 

“Business Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Buy-In” has the meaning set forth in Section 4.1(f). 

“Buy-In Price” has the meaning set forth in Section 4.1(f). 

“Certificate of Designation” means the Certificate of Designation to be filed prior to the Closing by the Company with
the Nevada Secretary of State, in the form of Exhibit H attached hereto. 

  
 2 

 “Closing” means the closing of the purchase and sale of the Shares and
the Warrants on the Closing Date pursuant to Section 2.1. 
 “Closing Bid Price” means, for any security as of
any date, (a) the last reported closing bid price per share for such security on the Principal Trading Market, as reported by Bloomberg Financial Markets, or, (b) if the Principal Trading Market begins to operate on an extended hours basis
and does not designate the closing bid price then the last bid price of such security prior to 4:00 p.m., New York City time, as reported by Bloomberg Financial Markets, or (c) if the foregoing do not apply, the last closing price of such
security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, (d) if no closing bid price is reported for such security by Bloomberg Financial Markets, the average of
the bid prices of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC. If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid
Price of such security on such date shall be the fair market value as mutually determined by the Company and the holder of such security. If the Company and such holder are unable to agree upon the fair market value of such security, then the Board
of Directors shall use its good faith judgment to determine the fair market value. The Board of Directors’ determination shall be binding on all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any
stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 
 “Closing
Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all of the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied or waived,
as the case may be, or such other date as the parties may agree. 
 “Commission” has the meaning set forth in the
Recitals. 
 “Common Shares” has the meaning set forth in the Recitals. 

“Common Stock” has the meaning set forth in the Recitals, and also includes any other class of securities into which
the Common Stock may hereafter be reclassified or changed. 
 “Common Stock Equivalents” means any securities of the
Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock or other securities that entitle the holder to receive, directly or indirectly, Common Stock. 

“Company” has the meaning set forth in the Preamble. 

“Company Counsel” means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial
Center, Boston, Massachusetts 02111. 

  
 3 

 “Company Covered Person” means, with respect to the Company as an
“issuer” for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1). 

“Company Deliverables” has the meaning set forth in Section 2.2(a). 

“Company’s Knowledge” means with respect to any statement made to the Company’s Knowledge, that the
statement is based upon the actual knowledge of the officers of the Company having responsibility for the matter or matters that are the subject of the statement, after reasonable inquiry. 

“Control” (including the terms “controlling”, “controlled by” or “under common control
with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Co-Placement Agent” has the meaning set forth in the Recitals. 

“Deadline Date” has the meaning set forth in Section 4.1(f). 

“Disclosure Materials” has the meaning set forth in Section 3.1(h). 

“Disclosure Schedules” has the meaning set forth in Section 3.1. 

“DTC” has the meaning set forth in Section 4.1(c). 

“Effective Date” means the date on which the initial Registration Statement required by Section 2(a) of the
Registration Rights Agreement is first declared effective by the Commission. 
 “Environmental Laws” has the meaning
set forth in Section 3.1(dd). 
 “Evaluation Date” has the meaning set forth in Section 3.1(t). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and
regulations promulgated thereunder. 
 “FDA” has the meaning set forth in Section 3.1(ll). 

“GAAP” means U.S. generally accepted accounting principles, as applied by the Company. 

“Intellectual Property Rights” has the meaning set forth in Section 3.1(p). 

“Irrevocable Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent
Instructions, in substantially the form of Exhibit E, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent. 

“Lead Investor” has the meaning set forth in Section 4.15. 

  
 4 

 “Lien” means any lien, charge, claim, encumbrance, security interest,
right of first refusal, preemptive right or other restrictions of any kind. 
 “Material Adverse Effect” means a
material adverse effect on the results of operations, assets, prospects, business or financial condition of the Company, except that any of the following, either alone or in combination, shall not be deemed a Material Adverse Effect:
(i) effects caused by changes or circumstances affecting general market conditions in the U.S. or applicable foreign economy or which are generally applicable to the industry in which the Company operates, provided that such effects are not
borne disproportionately by the Company, or (ii) effects caused by earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or
terrorism or military actions existing as of the date hereof. 
 “Material Contract” means any contract of the
Company that has been filed or was required to have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 

“Material Permits” has the meaning set forth in Section 3.1(n). 

“New York Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan. 

“Nevada Counsel” means Brownstein Hyatt Farber Schreck, LLP, with offices located at 100 North City Parkway, Suite
1600, Las Vegas, Nevada 89106. 
 “OFAC” has the meaning set forth in Section 3.1(kk). 

“Outside Date” means the tenth (10th) Business Day following
the date of this Agreement. 
 “Person” means an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Placement Agent” has the meaning set forth in the Recitals. 

“Pre-Notice” has the meaning set forth in Section 4.15. 

“Preferred Shares” has the meaning set forth in the Recitals. 

“Preferred Stock” has the meaning set forth in the Recitals. 

“Press Release” has the meaning set forth in Section 4.6. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for
trading, which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Capital Market. 

  
 5 

 “Pro Rata Portion” means, with respect to any Purchaser, the ratio of
(i) such Purchaser’s Subscription Amount and (ii) the aggregate sum of the Subscription Amounts for all of the Purchasers. 

“Proceeding” means an Action, claim, suit, investigation or proceeding (including, without limitation, an
investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
 “Purchase Price”
means $2.015 per unit, with $1.94 of each unit attributable to the share of Common Stock or Preferred Stock (for such purpose, counting the Preferred Shares with reference to the number of Underlying Shares), as applicable, included therein and
$0.075 of each unit attributable to the Warrants included therein to purchase 0.60 Warrant Shares. 
 “Purchaser” or
“Purchasers” has the meaning set forth in the Recitals. 
 “Purchaser Deliverables” has the
meaning set forth in Section 2.2(b). 
 “Purchaser Party” has the meaning set forth in Section 4.10. 

“Registration Rights Agreement” has the meaning set forth in the Recitals. 

“Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights
Agreement and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement). 

“Regulation D” has the meaning set forth in the Recitals. 

“Required Approvals” has the meaning set forth in Section 3.1(e). 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Reports” has the meaning set forth in Section 3.1(h). 

“Secretary’s Certificate” has the meaning set forth in Section 2.2(a)(vii). 

“Securities” has the meaning set forth in the Recitals. 

“Securities Act” has the meaning set forth in the Recitals. 

“Shares” has the meaning set forth in the Recitals. 

“Short Sales” include, without limitation, (i) all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in
Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or foreign regulated brokers (but shall not be deemed to include the
location and/or reservation of borrowable shares of Common Stock). 

  
 6 

 “Stock Certificates” has the meaning set forth in
Section 2.2(a)(ii). 
 “Subscription Amount” means, with respect to each Purchaser, the aggregate amount to be
paid for the Shares and the related Warrants purchased hereunder as indicated on such Purchaser’s signature page to this Agreement next to the heading “Aggregate Purchase Price (Subscription Amount)” in United States dollars and in
immediately available funds. 
 “Subsequent Financing” has the meaning set forth in Section 4.15. 

“Subsequent Financing Notice” has the meaning set forth in Section 4.15. 

“Subsidiary” means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable,
include any subsidiary of the Company formed or acquired after the date hereof. 
 “Trading Affiliate” has the
meaning set forth in Section 3.2(h). 
 “Trading Day” means (i) a day on which the Common Stock is listed
or quoted and traded on its Principal Trading Market (other than the OTCMarkets), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTCMarkets), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTCMarkets, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the
over-the-counter market as reported in the “pink sheets” by Pink Sheets LLC (or any similar organization or agency succeeding to its functions of reporting
prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE Mkt, the NASDAQ Global Select Market, the
NASDAQ Global Market, the NASDAQ Capital Market or the OTCMarkets on which the Common Stock is listed or quoted for trading on the date in question. 

“Tranche A Warrant” has the meaning set forth in Section 2.1(a). 

“Tranche B Warrant” has the meaning set forth in Section 2.1(a). 

“Transaction Documents” means this Agreement, the schedules and exhibits attached hereto, the Warrants, the
Registration Rights Agreement, the Irrevocable Transfer Agent Instructions and any other documents or agreements explicitly contemplated hereunder. 

“Transfer Agent” means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing
address of P.O. Box 30170, College Station, TX 77842-3170, and a telephone number of (877) 373-6374 from the United States, Canada and Puerto Rico and (781) 575-3100 from all other locations, or any successor transfer agent for the
Company. 

  
 7 

 “Warrant Shares” has the meaning set forth in the Recitals. 

“Warrants” has the meaning set forth in the Recitals. 

ARTICLE II 
 PURCHASE AND SALE 

2.1 Closing. 
 (a) Amount.
Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number of units equal to the
quotient resulting from dividing (i) the Subscription Amount for such Purchaser as indicated below such Purchaser’s name on its signature page to this Agreement by (ii) the Purchase Price, rounded down to the nearest whole Share. A
“unit” shall consist of (x) one share of Common Stock or 0.001 shares of Preferred Stock, as applicable, (y) a Warrant to purchase 0.40 Warrant Shares at an exercise price of $2.00 per share (a “Tranche A
Warrant”) and (z) a Warrant to purchase 0.20 Warrant Shares at an exercise price of $3.00 per share (a “Tranche B Warrant”), subject to adjustment as provided in such Warrants. 

(b) Closing. The Closing of the purchase and sale of the Shares and Warrants shall take place at the offices of Goodwin Procter LLP, The New
York Times Building, 620 Eighth Avenue, New York, New York 10018 on the Closing Date or at such other location(s) or remotely by facsimile transmission or other electronic means as the parties may mutually agree. 

(c) Form of Payment. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on or prior to the Business Day
immediately prior to the Closing Date, each Purchaser shall wire its Subscription Amount, in United States dollars and in immediately available funds, to a bank account designated by the Company. 

(d) On the Closing Date, upon receipt of the aggregate Purchase Price: (i) the Company shall irrevocably instruct the Transfer Agent to
deliver to each Purchaser (within three Trading Days after the Closing) one or more stock certificates, free and clear of all restrictive and other legends (except as expressly provided in Section 4.1(b) hereof), evidencing the number of Shares
such Purchaser is purchasing as is set forth on such Purchaser’s signature page to this Agreement next to the heading “Number and Type of Shares to be Acquired,” , and (ii) the Company shall on the Business Day following the
Closing Date send for overnight delivery to each Purchaser one or more Tranche A Warrants and one or more Tranche B Warrants, free and clear of all restrictive and other legends (except as expressly provided in Section 4.1(b) hereof),
evidencing the number of Warrant Shares such Purchaser is entitled to purchase as is set forth on such Purchaser’s signature page to this Agreement next to the heading “Warrant Shares Subject to Warrant.” 

  
 8 

 2.2 Closing Deliveries. 

(a) On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser the following (the
“Company Deliverables”): 
 (i) this Agreement, duly executed by the Company; 

(ii) facsimile copies of one or more stock certificates, free and clear of all restrictive and other legends (except as provided in
Section 4.1(b) hereof), evidencing the Shares subscribed for by such Purchaser hereunder, registered in the name of such Purchaser as set forth on the Stock Certificate Questionnaire included as Exhibit C-2 hereto (the “Stock
Certificates”), with the original Stock Certificates delivered by the Transfer Agent within three Trading Days of Closing; 

(iii) facsimile copies of one or more Warrants, executed by the Company and registered in the name of such Purchaser as set forth on the
Stock Certificate Questionnaire included as Exhibit C-2 hereto, pursuant to which such Purchaser shall have the right to acquire such number of Warrant Shares equal to 60% of the number of Shares (for such purpose, counting the Preferred
Shares with reference to the number of Underlying Shares) issuable to such Purchaser pursuant to Section 2.2(a)(ii), rounded up to the nearest whole share (provided, however, that in the event any Purchasers are Affiliates of each other,
all Shares purchased by such Purchasers shall be aggregated together for the purpose of determining the aggregate number of Warrant Shares subject to all Warrants purchased by such Purchasers), on the terms set forth therein, with the original
Warrants to be sent on the Business Day following the Closing Date for overnight delivery to the Purchasers; 
 (iv) a legal opinion of
(A) Company Counsel, dated as of the Closing Date and in substantially the form attached hereto as Exhibit D-1, executed by such counsel and addressed to the Purchasers, the Placement Agent and the Co-Placement Agents, and
(B) Nevada Counsel, dated as of the Closing Date and in substantially the form attached hereto as Exhibit D-2, executed by such counsel and addressed to the Purchasers, the Placement Agent and the Co-Placement Agents; 

(v) the Registration Rights Agreement, duly executed by the Company; 

(vi) duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent instructing the Transfer Agent to
deliver, on an expedited basis, a certificate evidencing a number of Shares equal to such Purchaser’s Subscription Amount divided by the Purchase Price, registered in the name of such Purchaser; 

(vii) a certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date and in substantially the form attached hereto as Exhibit F; 
 (viii) the Compliance Certificate referred to in
Section 5.1(h); 
 (ix) a certificate evidencing the formation and good standing of the Company issued by the Nevada Secretary of
State as of a date within five days of the Closing Date; 

  
 9 

 (x) a certificate evidencing the Company’s qualification as a foreign corporation and good
standing issued by the Secretary of the Commonwealth of the Commonwealth of Massachusetts as of a date within five days of the Closing Date; and 

(xi) a certified copy of the articles of incorporation of the Company (which shall include the Certificate of Designation), as certified by
the Nevada Secretary of State, as of a date within 10 days of the Closing Date; 
 (b) On or prior to the Closing, each Purchaser shall
deliver or cause to be delivered to the Company (or the Placement Agent in the case of clause (ii) below) the following, with respect to such Purchaser (the “Purchaser Deliverables”): 

(i) this Agreement, duly executed by such Purchaser; 

(ii) subject to the completion of Section 2.2(a)(ii) and (iii), its Subscription Amount, in United States dollars and in immediately
available funds, in the amount set forth as the “Purchase Price” indicated below such Purchaser’s name on the applicable signature page hereto under the heading “Aggregate Purchase Price (Subscription Amount)” by wire
transfer to a bank account designated by the Company; 
 (iii) the Registration Rights Agreement, duly executed by such Purchaser; 

(iv) a fully completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex B to the Registration Rights
Agreement; and 
 (v) a fully completed and duly executed Accredited Investor Questionnaire, satisfactory to the Company, and Stock
Certificate Questionnaire in the forms attached hereto as Exhibits C-1 and C-2, respectively. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES 

3.1 Representations and Warranties of the Company. Except as (i) set forth in the schedules delivered herewith (the
“Disclosure Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosure contained in the corresponding section of the Disclosure
Schedules, or (ii) disclosed in the SEC Reports, the Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of
such date), to each of the Purchasers, the Placement Agent and the Co-Placement Agents: 
 (a) Subsidiaries. The Company has no direct or
indirect Subsidiaries other than those listed in Schedule 3.1(a) hereto. Except as disclosed in Schedule 3.1(a) hereto, the Company owns, directly or indirectly, all of the capital stock or comparable equity interests of each
Subsidiary free and clear of any and all Liens, and all the issued and outstanding shares of capital stock or comparable equity interest of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities. 

  
 10 

 (b) Organization and Qualification. The Company and each of its Subsidiaries is an entity duly
incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite corporate power and authority to own or lease and use its
properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its articles of incorporation or bylaws or other organizational documents. The
Company and each of its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted, is pending, or, to
the Company’s Knowledge, has been threatened in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. 

(c) Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The Company’s execution and delivery of each of the Transaction Documents to which it is
a party and the consummation by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares and the Warrants and the reservation for issuance and the subsequent issuance of the Warrant
Shares upon exercise of the Warrants) have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate action is required by the Company, its Board of Directors or its stockholders in connection
therewith other than in connection with the Required Approvals. Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly executed by the Company and is, or when delivered in accordance with the terms
hereof, will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 

(d) No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of the Shares and Warrants and the reservation for issuance and issuance of the Warrant Shares) do not and will not
(i) conflict with or violate any provisions of the Company’s or any Subsidiary’s articles of incorporation or bylaws or other similar organizational documents of any Subsidiary, (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would result in a default) under, result in the creation of any Lien upon any of the properties or 

  
 11 

 
assets of the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material
Contract, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a
Subsidiary is subject (including federal and state securities laws and regulations and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to
which the Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company is bound or affected, except in the case of clauses (ii) and (iii) such as would not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect or a material adverse effect on the legality, validity or enforceability of any Transaction Document or the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document. 
 (e) Filings, Consents and Approvals. Neither the Company nor
any of its Subsidiaries is required to obtain any consent, waiver, approval, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority, holder of
outstanding securities of the Company or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including the issuance of the Securities), other than (i) the filing with the
Commission of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities on
Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for the issuance and sale of the Securities and the listing of the Shares and
Warrant Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with Section 4.6 of this Agreement and (vi) those that have been made or obtained
prior to the date of this Agreement (collectively, the “Required Approvals”). 
 (f) Issuance of the Securities. The
Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions on
transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights of stockholders. The Warrants have been duly authorized and, when issued and paid for in accordance
with the terms of the Transaction Documents, will be duly and validly issued, free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be
subject to preemptive or similar rights of stockholders. The Warrant Shares issuable upon exercise of the Warrants have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents and the Warrants,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to
preemptive or similar rights of stockholders. Assuming the accuracy of the representations and warranties of the Purchasers in this Agreement, the Securities will be issued in compliance with all applicable federal and state

  
 12 

 
securities laws. As of the Closing Date, the Company shall have reserved from its duly authorized capital stock the number of shares of Common Stock issuable upon exercise of the Warrants
(without taking into account any limitations on the exercise of the Warrants set forth in the Warrants). The Company shall, so long as any of the Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized
and unissued capital stock, solely for the purpose of effecting the exercise of the Warrants, the number of shares of Common Stock issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants
set forth in the Warrants). No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s
knowledge, any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable. 

(g) Capitalization. The capitalization of the Company is as described in its most recently filed SEC Report on Form 10-K, except for issuances
pursuant to this Agreement, stock option exercises, issuances pursuant to equity incentive plans or exercises of warrants. The Company has not issued any capital stock since the date of its most recently filed SEC Report other than to reflect stock
option and warrant exercises that do not, individually or in the aggregate, have a material affect on the issued and outstanding capital stock, options and other securities of the Company. No Person has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents that have not been effectively waived as of the Closing Date. Except as set forth on Schedule 3.1(g) or a result of
the purchase and sale of the Shares and Warrants, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock Equivalents. Except as set forth on Schedule 3.1(g), the issuance and sale of the Shares and Warrants will not obligate the Company to issue shares of Common Stock or other securities to any
Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been issued in compliance in all material respects with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive
rights or similar rights to subscribe for or purchase securities which violation would have or would reasonably be expected to result in a Material Adverse Effect. There are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company’s capital stock to which the Company is a party or, to the Company’s Knowledge, between or among any of the Company’s stockholders. 

(h) SEC Reports; Disclosure Materials. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”, and the SEC Reports, together with the Disclosure Schedules, being
collectively referred to as the “Disclosure  

  
 13 

 
Materials”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension, except
where the failure to file on a timely basis would not have or reasonably be expected to result in a Material Adverse Effect and would not have or reasonably be expected to result in any limitation or prohibition on the Company’s ability to
register the Shares and Warrant Shares for resale on Form S-1 or any Purchaser’s ability to use Rule 144 to resell any Securities. As of their respective filing dates, or to the extent corrected by a subsequent amendment, the SEC Reports
complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Each of the Material Contracts to which
the Company or any Subsidiary is a party or to which the property or assets of the Company or any of its Subsidiaries are subject has been filed (or incorporated by reference) as an exhibit to the SEC Reports. 

(i) Financial Statements. The consolidated financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent amendment). Such consolidated financial statements have been
prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all
footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries taken as a whole as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial year-end audit adjustments. 
 (j) Material Changes.
Since the date of the latest financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof and except as disclosed in Schedule 3.1(j), (i) there have been
no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or
otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to
GAAP or required to be disclosed in filings made with the Commission, (iii) the Company has not altered materially its method of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock
issued to employees of the Company) and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock issued in the ordinary course as dividends on outstanding preferred stock or issued pursuant
to existing Company stock option or stock purchase plans or executive and director compensation arrangements disclosed in the SEC Reports. Except as disclosed in Schedule 3.1(j) and except for the issuance of the Shares and Warrants
contemplated by this Agreement, no event, liability or development has 

  
 14 

 
occurred or exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the
Company under applicable securities laws at the time this representation is made that has not been publicly disclosed at least one Trading Day prior to the date that this representation is made. 

(k) Litigation. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) except as disclosed in Schedule 3.1(k), would, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse
Effect. During the past five years, neither the Company nor any Subsidiary, nor to the Company’s Knowledge any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or
state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director
or officer of the Company. During the past five years, the Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act. 

(l) Employment Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees
of the Company which would have or would reasonably be expected to result in a Material Adverse Effect. None of the Company’s or any Subsidiary’s employees is a member of a labor union that relates to such employee’s relationship with
the Company, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. Except as disclosed in Schedule 3.1(l), no executive officer of the Company (as defined in Rule 501(f) of the Securities Act)
has notified the Company or any of its Subsidiaries that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. To the Company’s Knowledge,
no executive officer or key employee, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or
agreement or any restrictive covenant in favor of any third party, and to the Company’s Knowledge, the continued employment of each such executive officer or key employee does not subject the Company or any Subsidiary to any liability with
respect to any of the foregoing matters, except, in each case, matters that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. The Company is in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect. 
 (m) Compliance. Neither the Company nor any of its Subsidiaries (i) is in default
under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries under), nor has the Company or any of its Subsidiaries
received written notice of a claim that it is in default under or that it is in violation of, any Material Contract (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator

  
 15 

 
or governmental body having jurisdiction over the Company or any of its Subsidiaries or their properties or assets, or (iii) is in violation of, or in receipt of written notice that it is in
violation of, any statute, rule or regulation of any governmental authority applicable to the Company or any of its Subsidiaries, except in each case as would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect. 
 (n) Regulatory Permits. The Company and each of its Subsidiaries possesses all certificates, authorizations and
permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its business as currently conducted, except as set forth in the SEC Reports, or such that where the failure to possess such permits,
individually or in the aggregate, has not and would not have or would not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any of its Subsidiaries has received
any notice of Proceedings relating to the revocation or modification of any such Material Permits. 
 (o) Title to Assets. The Company and
each of its Subsidiaries has good and marketable title to all tangible personal property owned by it that is material to its business, in each case free and clear of all Liens except such as do not materially affect the value of such property and do
not interfere with the use made and proposed to be made of such property by the Company. Any real property and facilities held under lease by the Company and any of its Subsidiaries are held by it under valid, subsisting and enforceable leases with
such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 

(p) Patents and Trademarks. Except as disclosed in Schedule 3.1(p), to the Company’s Knowledge, the Company and each of its
Subsidiaries owns, possesses, licenses or has other rights to use, all patents, patent applications, trade and service marks, trade and service mark applications and registrations, trade names, trade secrets, inventions, copyrights, licenses,
technology, know-how and other intellectual property rights and similar rights necessary or material for use in connection with its businesses as described in the SEC Reports and which the failure to so would have or reasonably be expected to result
in a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Except as disclosed in Schedule 3.1(p), to the Company’s Knowledge, none of the Intellectual Property Rights used by the Company or
any Subsidiary violates or infringes upon the patent, trademark, copyright, trade secret or other proprietary rights of any Person. There is no pending or, to the Company’s Knowledge, threatened Proceeding or claim by any Person that the
Company’s or any Subsidiary’s business as now conducted infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of another. To the Company’s Knowledge, there is no existing
infringement by another Person of any of the Intellectual Property Rights that would have or would reasonably be expected to result in a Material Adverse Effect. There is no pending or, to the Company’s Knowledge, threatened Proceeding or claim
by another Person challenging the Company’s or any Subsidiary’s rights in or to any material Intellectual Property Rights, or challenging inventorship, validity or scope of any such Intellectual Property Rights. The Company has taken
reasonable security measures to protect the secrecy, confidentiality and value of all of its and its Subsidiaries’ Intellectual Property Rights, except where failure to do so would not, individually or in the aggregate, reasonably be expected
to result in a Material Adverse Effect. None of the technology employed by the Company or any of its Subsidiaries has 

  
 16 

 
been obtained or is being used by the Company or any Subsidiary in violation of any contractual obligation binding on the Company or any Subsidiary or, to the Company’s Knowledge, any of its
or its Subsidiaries’ officers, directors or employees or otherwise in violation of the rights of any Person, which violations would have or would reasonably be expected to have a Material Adverse Effect. 

(q) Insurance. The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as the Company believes to be prudent and customary in the businesses and locations in which the Company and the Subsidiaries are engaged. None of the Company or any of its Subsidiaries has received any written notice of
cancellation of any such insurance, nor, to the Company’s Knowledge, will it or any Subsidiary be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business without a material increase in cost. 
 (r) Transactions With Affiliates and Employees. Except as set
forth in the SEC Reports, none of the executive officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than for services as
employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated under the Securities Act. 

(s) Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets and
liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. 

(t) Sarbanes-Oxley; Disclosure Controls. The Company is in compliance in all material respects with all of the provisions of the
Sarbanes-Oxley Act of 2002 which are applicable to it. The Company has established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for the Company and designed such disclosure
controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by the Company’s most recently filed
periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s internal control over financial reporting (as such term is
defined in the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. 

  
 17 

 (u) Certain Fees. Except as disclosed in Schedule 3.1(u), no Person will have, as a result
of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by
or on behalf of the Company, other than the Placement Agent and the Co-Placement Agents with respect to the offer and sale of the Shares and Warrants (which fees are being paid by the Company). The Purchasers shall have no obligation with respect to
any fees or with respect to any claim made by or on behalf of other Persons for fees of a type contemplated in this paragraph (u) pursuant to any agreement to which the Company is a party that may be due in connection with the transactions
contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each Purchaser harmless against, any liability, loss or expense (including, without limitation, attorneys’ fees and out-of-pocket expenses) arising in
connection with any such right, interest or claim. 
 (v) Private Placement. Assuming the accuracy of the Purchasers’ representations
and warranties set forth in Section 3.2 of this Agreement and the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers, no registration under the Securities Act is required for the offer and
sale of the Securities by the Company to the Purchasers under the Transaction Documents. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Trading Market. 

(w) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares and Warrants,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become subject to the Investment
Company Act of 1940, as amended. 
 (x) Registration Rights. Other than each of the Purchasers pursuant to the Registration Rights Agreement
or as disclosed in Schedule 3.1(x), no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company. 

(y) Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the
Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.
The Company has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Company is in compliance with all listing and maintenance requirements of the Principal Trading Market on the date hereof and the issuance of the Securities will not violate any such listing or maintenance
requirements. 
 (z) Application of Takeover Protections; Rights Agreements. The Company and the Board of Directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under 

  
 18 

 
a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of its state of incorporation that is
or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation, the
Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. 
 (aa) Disclosure. The Company confirms
that it has not provided, and to the Company’s Knowledge, none of its officers or directors nor any other Person acting on its or their behalf has provided, and it has not authorized the Placement Agent or the Co-Placement Agents to provide,
any Purchaser or its respective agents or counsel with any information that it believes constitutes material, non-public information except insofar as the existence, provisions and terms of the Transaction Documents and the proposed transactions
hereunder may constitute such information, all of which will be disclosed by the Company in the Press Release as contemplated by Section 4.6 hereof. The Company understands and confirms that the Purchasers will rely on the foregoing
representations in effecting transactions in securities of the Company. 
 (bb) No Integrated Offering. Assuming the accuracy of the
Purchasers’ representations and warranties set forth in Section 3.2, neither the Company nor, to the Company’s Knowledge, any Person acting on its behalf has, directly or indirectly, at any time within the past six months, made any
offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with
the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable
law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market on which any of the securities of the Company are listed or designated unless such integration would not have or
reasonably be expected to result in a Material Adverse Effect. 
 (cc) Tax Matters. The Company and each of its Subsidiaries (i) has
accurately and timely prepared and filed (or requested valid extensions thereof) all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all
taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith, with respect to which adequate reserves have been
set aside on the books of the Company and (iii) has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply, except, in the
case of clauses (i) and (ii) above, where the failure to so pay or file any such tax, assessment, charge or return would not have or reasonably be expected to result in a Material Adverse Effect. The Company has not received notice of any
unpaid taxes in any material amount claimed to be due by the Company or any Subsidiary by the taxing authority of any jurisdiction. 
 (dd)
Environmental Matters. To the Company’s Knowledge, none of the Company or any of its Subsidiaries (i) is in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign,
relating to the use, 

  
 19 

 
disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively,
“Environmental Laws”), (ii) owns or operates any real property contaminated with any substance that is in violation of any Environmental Laws, (iii) is liable for any off-site disposal or contamination pursuant to
any Environmental Laws, or (iv) is subject to any claim relating to any Environmental Laws; which violation, contamination, liability or claim has had or would have, individually or in the aggregate, a Material Adverse Effect; and there is no
pending investigation or, to the Company’s Knowledge, investigation threatened in writing that might lead to such a claim. 
 (ee) No
General Solicitation. Neither the Company nor, to the Company’s Knowledge, any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. 

(ff) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company, any Subsidiary and an
unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in the SEC Reports and is not so disclosed and would have or reasonably be expected to result in a Material Adverse Effect. 

(gg) Foreign Corrupt Practices. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any agent or other
Person acting on behalf of the Company or any of its Subsidiaries, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company
or any Subsidiary (or made by any Person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

(hh) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is
acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor
or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection
with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into
this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 

(ii) Regulation M Compliance. The Company has not, and to the Company’s Knowledge no one acting on its behalf has, (i) taken,
directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the 

  
 20 

 
Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities in violation of
Regulation M under the Exchange Act, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid
to the Placement Agent and the Co-Placement Agents in connection with the placement of the Shares and Warrants. 
 (jj) PFIC Status. Neither
the Company nor any of its Subsidiaries is or intends to become a “passive foreign investment company” within the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as amended. 

(kk) OFAC Status. Neither the Company nor any of its Subsidiaries is and, to the Company’s Knowledge, no director, officer, agent,
employee, Affiliate or Person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the
Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other Person or entity, towards any sales or operations in Cuba,
Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for the purpose of financing the activities of any Person currently subject to any U.S. sanctions administered by OFAC. 

(ll) FDA. There is no legal or governmental proceeding to which the Company or any Subsidiary is a party or of which any property or assets of
the Company or any Subsidiary is the subject, including any proceeding before the United States Food and Drug Administration of the U.S. Department of Health and Human Services (“FDA”) or comparable federal, state, local or
non-U.S. governmental bodies (it being understood that the interaction between the Company and the FDA and such comparable governmental bodies relating to the clinical development and product approval process shall not be deemed proceedings for
purposes of this representation), which, singularly or in the aggregate, if determined adversely to the Company or any Subsidiary, would have or would reasonably be expected to have a Material Adverse Effect; and to the Company’s Knowledge, no
such proceedings are threatened or contemplated by governmental authorities or threatened by others. The Company and each Subsidiary is in compliance with all applicable federal, state, local and non-U.S. laws, regulations, orders and decrees
governing its business as prescribed by the FDA, or any other federal, state or non-U.S. agencies or bodies engaged in the regulation of pharmaceuticals, except where noncompliance would not, singularly or in the aggregate, be reasonably likely to
have a Material Adverse Effect. All preclinical studies and clinical trials conducted by or on behalf of the Company and any subsidiary, including those necessary to support approval for commercialization of the Company’s or any
Subsidiary’s products or product candidates, have been conducted by the Company or any Subsidiary, as applicable, or to the Company’s Knowledge by third parties, in material compliance with all applicable federal, state or non-U.S. laws,
rules, orders and regulations. 
 (mm) No Additional Agreements. The Company does not have any agreement or understanding with any Purchaser
with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents. 

  
 21 

 3.2 Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself
and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the Company, the Placement Agent and the Co-Placement Agents as follows: 

(a) Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with the requisite corporate, limited liability company or partnership power and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate
or, if such Purchaser is not a corporation, such partnership, limited liability company or other applicable like action, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and
when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. 

(b) No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights Agreement and the
consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or
violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder. 

(c) Investment Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered under
the Securities Act or any applicable state securities law and is acquiring the Shares and Warrants and, upon exercise of the Warrants, will acquire the Warrant Shares issuable upon exercise thereof as principal for its own account and not with a
view to, or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities laws, provided, however, that by making the representations herein, such Purchaser does not
agree to hold any of the Securities for any minimum period of time and reserves the right, subject to the provisions of this Agreement and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such
Securities pursuant to an effective registration statement under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws. Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business. Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute or effect any distribution of any of the Securities (or

  
 22 

 
any securities which are derivatives thereof) to or through any Person; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a
business that would require it to be so registered as a broker-dealer. 
 (d) Purchaser Status. At the time such Purchaser was offered the
Shares and Warrants, it was, and at the date hereof it is, and on each date on which it exercises the Warrants it will be, an “accredited investor” as defined in Rule 501(a) under the Securities Act. 

(e) General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general advertisement. 

(f) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 
 (g)
Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Disclosure Materials and has been afforded the opportunity to ask such questions as it has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the offering of the Securities. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify,
amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness of the Company’s representations and warranties contained in the Transaction Documents. 

(h) Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or
claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Purchaser. 

(i) Independent Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant to
the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s business and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other
materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. Such Purchaser understands that the Placement Agent and the Co-Placement Agents has acted solely as the agents of the Company in this placement
of the Shares and Warrants and such Purchaser has not relied on the business or legal advice of the Placement Agent or the Co-Placement Agents or any of their respective agents, counsel or Affiliates in making its investment decision hereunder, and
confirms that none of such Persons has made any representations or warranties to such Purchaser in connection with the transactions contemplated by the Transaction Documents. 

  
 23 

 (j) Reliance on Exemptions. Such Purchaser understands that the Securities are being offered and
sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s compliance with,
the representations, warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. 

(k) No Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. 

(l) Residency. Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the Securities
was made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto. 
 (m)
Accuracy of Accredited Investor Questionnaire. The Accredited Investor Questionnaire delivered by such Purchaser in connection with this Agreement is complete and accurate in all respects as of the date of this Agreement and will be correct as
of the Closing Date. 
 The Company and each of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction Documents. 

ARTICLE IV 
 OTHER AGREEMENTS OF
THE PARTIES 
 4.1 Transfer Restrictions. 

(a) Compliance with Laws. Notwithstanding any other provision of this Article IV, each Purchaser, severally but not jointly, covenants that the
Securities may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Securities other than (i) pursuant to an effective registration statement,
(ii) to the Company, (iii) pursuant to Rule 144 (provided that such Purchaser provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities may be sold
pursuant to such rule) or (iv) in connection with a bona fide pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and
reasonably acceptable to the 

  
 24 

 
Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities
under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights of a Purchaser under this Agreement and the
Registration Rights Agreement with respect to such transferred Securities. 
 (b) Legends. Certificates evidencing the Securities shall bear
any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form, until such time as they are not required under Section 4.1(c): 

[NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED] [THESE SECURITIES HAVE NOT BEEN
REGISTERED] UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN
EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. 

The Company acknowledges and agrees that a Purchaser may from time to time pledge, and/or grant a security interest in, some or all of the
legended Securities in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan. Such a pledge would not be subject to approval or consent of the Company and no legal opinion of
legal counsel to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection with a subsequent transfer or foreclosure following default by such Purchaser transferee
of the pledge. No notice shall be required of such pledge, but such Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure of such legended Securities. Each Purchaser acknowledges that the
Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Securities or for any agreement, understanding or arrangement between any Purchaser and its pledgee or secured party. At the
appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including the
preparation and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the 

  
 25 

 
Securities Act to appropriately amend the list of selling stockholders thereunder. Each Purchaser acknowledges and agrees that, except as otherwise provided in Section 4.1(c), any Securities
subject to a pledge or security interest as contemplated by this Section 4.1(b) shall continue to bear the legend set forth in this Section 4.1(b) and be subject to the restrictions on transfer set forth in Section 4.1(a). 

(c) Removal of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall issue a certificate or
book-entry statement without such legend or any other legend to the holder of the applicable Securities upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account at the Depository Trust Company
(“DTC”), if (i) such Securities are registered for resale under the Securities Act (provided that, if a Purchaser is selling pursuant to the Registration Statement, such Purchaser agrees to only sell such Securities
during such time that the Registration Statement is effective and not withdrawn or suspended, and only as permitted by the Registration Statement), (ii) such Securities are sold or transferred pursuant to Rule 144 (if the transferor is not an
Affiliate of the Company), or (iii) such Securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and without
volume or manner-of-sale restrictions. Following the earlier of (i) the Effective Date or (ii) Rule 144 becoming available for the resale of Securities, without the requirement for the Company to be in compliance with the current public
information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions, the Company shall deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall reissue a certificate representing
the applicable Shares or issue a certificate representing the applicable Warrant Shares without legend upon receipt by the Transfer Agent of the legended certificates for such Shares. Any fees (with respect to the Transfer Agent or otherwise)
associated with the removal of such legend shall be borne by the Company. Following the Effective Date, or at such earlier time as a legend is no longer required for certain Securities (in which case a Purchaser shall also be required to provide
reasonable assurances, in the form of seller and, if applicable, broker representation letters), the Company will no later than three Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent (with notice to the
Company) of (i) a legended certificate representing Shares or Warrant Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer) or (ii) an Exercise
Notice and payment of the applicable exercise price in the manner stated in the Warrants to effect the exercise of such Warrant in accordance with its terms, and an opinion of counsel to the extent required by Section 4.1(a), deliver or cause
to be delivered to the transferee of such Purchaser or such Purchaser, as applicable, a certificate representing such Securities that is free from all restrictive and other legends. The Company may not make any notation on its records or give
instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.1(c) other than to comply with applicable law. Certificates or book entry statements for Shares or Warrant Shares subject to legend removal
hereunder may be transmitted by the Transfer Agent to a Purchaser by crediting the account of such Purchaser’s prime broker with DTC as directed by such Purchaser. 

(d) Irrevocable Transfer Agent Instructions. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent
transfer agent, in substantially the form of Exhibit E attached hereto (the “Irrevocable Transfer Agent Instructions”). The 

  
 26 

 
Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 4.1(d) (or instructions that are consistent therewith)
will be given by the Company to the Transfer Agent in connection with this Agreement, and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the
other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this Section 4.1(d) will cause irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Section 4.1(d) will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 4.1(d), that a Purchaser shall be entitled, in addition
to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. 

(e) Acknowledgement. Each Purchaser, severally but not jointly, acknowledges its primary responsibilities under the Securities Act and
accordingly will not sell or otherwise transfer the Securities or any interest therein without complying with the requirements of the Securities Act and applicable law. While the Registration Statement remains effective, each Purchaser hereunder may
sell the Shares and Warrant Shares in accordance with the plan of distribution contained in the Registration Statement and if it does so it will comply therewith and with the related prospectus delivery requirements unless an exemption therefrom is
available. Each Purchaser, severally and not jointly with the other Purchasers, agrees that if it is notified by the Company in writing at any time that the Registration Statement registering the resale of the Shares or the Warrant Shares is not
effective or that the prospectus included in such Registration Statement no longer complies with the requirements of Section 10 of the Securities Act, such Purchaser will refrain from selling such Shares and Warrant Shares until such time as
the Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is compliant with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell such Shares or Warrant Shares
pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act. Both the Company and its Transfer Agent, and their respective directors, officers, employees and agents, may rely on this
Section 4.1(e) and each Purchaser, severally but not jointly, with the other Purchasers will indemnify and hold harmless each of such persons from any breaches or violations of this Section 4.1(e). 

(f) Buy-In. If the Company shall fail for any reason or for no reason to issue to a Purchaser unlegended certificates or book-entry statements
within three Trading Days after receipt of all documents necessary for the removal of the legend set forth above (the “Deadline Date”), then, in addition to all other remedies available to such Purchaser, if on or after the
Trading Day immediately following such three Trading Day period, such Purchaser is required to purchase (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the holder of shares of Common Stock
that such Purchaser anticipated receiving from the Company without any restrictive legend (a “Buy-In”), then the Company shall, within three Trading Days after such Purchaser’s request and in the Company’s sole
discretion, either (i) pay cash to such Purchaser in an amount equal to such Purchaser’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the shares of Common Stock held by such Purchaser equal to the number of shares of Common Stock so purchased shall be forfeited to the 

  
 27 

 
Company and the Company’s obligation to deliver such certificate or book-entry statement (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor its
obligation to deliver to such Purchaser a certificate or certificates or book-entry statements representing such shares of Common Stock and pay cash to the Purchaser in an amount equal to the excess (if any) of the Buy-In Price over the product of
(a) such number of shares of Common Stock, multiplied by (b) the Closing Bid Price on the Deadline Date. A Purchaser shall provide the Company written notice indicating the amounts payable to such Purchaser in respect of the Buy-In,
together with applicable confirmations and other evidence reasonably requested by the Company. 
 4.2 Reservation of Common Stock.

 (a) The Company shall take all action necessary to at all times during the period the Warrants are outstanding have authorized, and
reserved for the purpose of issuance from and after the Closing Date, the number of shares of Common Stock issuable upon exercise of the Warrants issued at the Closing (without taking into account any limitations on exercise of the Warrants set
forth in the Warrants). 
 (b) The Company shall reserve and keep available at all times during which the Preferred Shares remain
outstanding, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Underlying Shares upon conversion of the Preferred Shares pursuant to the Certificate of Designation. The form
of Notice of Conversion included in the Certificate of Designation sets forth the totality of the procedures required of the Purchasers in order to convert the Preferred Shares. No additional legal opinion, other information or instructions shall be
required of the Purchasers to convert their Preferred Shares. The Company shall honor conversions of the Preferred Shares and shall deliver Underlying Shares in accordance with the terms, conditions and time periods set forth in the Transaction
Documents. 
 4.3 Acknowledgment of Dilution. The Company acknowledges that the issuance of the Shares may result in dilution of the
outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including without limitation its obligation to issue the
Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any
Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company. 

4.4 Furnishing of Information. In order to enable the Purchasers to sell the Securities under Rule 144, until the earlier of
(i) the date that the Securities cease to be Registrable Securities (as defined in the Registration Rights Agreement) (and for no less than 12 months from the Closing), (ii) the date that is 24 months from the Closing or (iii) a
Fundamental Transaction (as defined in the Warrant) pursuant to which the Company is no longer a reporting company under the Exchange Act, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. 

  
 28 

 
Except as set forth in clause (iii) above, during such period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and
make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144. 

4.5 No Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would
require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction. 

4.6 Securities Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following the
date hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Placement Agent disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York
City time, on the fourth Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to such
Current Report on Form 8-K the material Transaction Documents (including, without limitation, this Agreement, the form of Warrant and the Registration Rights Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the
name of any Purchaser or an Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or
Trading Market, without the prior written consent of such Purchaser, except (i) as required by federal securities law in connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the
filing of final Transaction Documents (including signature pages thereto) with the Commission and (ii) to the extent such disclosure is required by law, request of the Staff of the Commission or Trading Market regulations, in which case the
Company shall provide the Purchasers with prior written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information
received from the Company or any of its officers, directors, employees or agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement regarding confidentiality and use of such information. Each
Purchaser, severally and not jointly with the other Purchasers, covenants that it will comply with the provisions of any confidentiality or nondisclosure agreement executed by it and, in addition, until such time as the transactions contemplated by
this Agreement are required to be publicly disclosed by the Company as described in this Section 4.6, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). 
 4.7 Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent
of the Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution 

  
 29 

 
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such
plan or arrangement, in either case solely by virtue of receiving Securities under the Transaction Documents or under any other written agreement between the Company and the Purchasers. 

4.8 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or
counsel with any information regarding the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser, unless prior thereto such Purchaser shall have executed a written
agreement regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. 

4.9 Use of Proceeds. The Company shall use the net proceeds from the sale of the Shares and Warrants hereunder for working capital and
general corporate purposes. 
 4.10 Indemnification of Purchasers. Subject to the provisions of this Section 4.10, the Company
will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees
(and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and
all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party
may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (ii) any Action instituted
against a Purchaser in any capacity, or any Purchaser Party, by any stockholder of the Company who is not an Affiliate of such Purchaser seeking indemnification, with respect to any of the transactions contemplated by the Transaction Documents
(unless such Action is based upon a breach of such Purchaser’s representations, warranties or covenants under the Transaction Documents or any other agreement with the Company, or any agreements or understandings such Purchaser may have with
any such stockholder or any violations by the Purchaser of state or federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). Promptly after receipt by any such Person
(the “Indemnified Person”) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any Proceeding or investigation in respect of which indemnity may be sought pursuant
to this Section 4.10, such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall
assume the payment of all fees and 

  
 30 

 
expenses relating to such Proceeding or investigation; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations
hereunder except to the extent that the Company is actually and materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of such
proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel would be
inappropriate due to actual or potential differing interests between them. The Company shall not be liable for any settlement of any proceeding effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or
conditioned or to the extent fees or costs incurred pursuant to this Section 4.10 are attributable to the Indemnified Person’s breach of any of the representations, warranties, covenants or agreements made by the Purchasers in this
Agreement or the other Transaction Documents. Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or
threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement includes an unconditional release of such Indemnified
Person from all liability arising out of such proceeding. 
 4.11 Listing of Securities. In the time and manner required by the
Principal Trading Market, the Company shall prepare and file with such Principal Trading Market an additional shares listing application covering all of the Shares and Warrant Shares and shall use its reasonable best efforts to take all steps
necessary to cause all of the Shares and Warrant Shares to be approved for listing on the Principal Trading Market as promptly as possible thereafter. 

4.12 Form D; Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under
Regulation D and to provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take such action as the Company shall reasonably determine is necessary in order to obtain an
exemption for or to qualify the Securities for sale to the Purchasers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such
qualification) and shall provide evidence of such actions promptly upon the written request of any Purchaser. 
 4.13 Short Sales and
Confidentiality After The Date Hereof. Such Purchaser shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in any transactions in the Company’s securities (including, without limitation, any Short Sales
involving the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced as required by and described in Section 4.6
or (ii) this Agreement is terminated in full pursuant to Section 6.18. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly
disclosed by the Company as described in Section 4.5, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Transaction Documents and

  
 31 

 
Disclosure Schedules. Notwithstanding the foregoing, no Purchaser makes any representation, warranty or covenant hereby that it will not engage in Short Sales in the securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced as described in Section 4.5; provided, however, each Purchaser agrees, severally and not jointly with any Purchasers, that they will not
enter into any Net Short Sales (as hereinafter defined) from the period commencing on the Closing Date and ending on the earliest of (x) the Effective Date of the initial Registration Statement, (y) the second anniversary of the Closing
Date or (z) the date that such Purchaser no longer holds any Securities. For purposes of this Section 4.13, a “Net Short Sale” by any Purchaser shall mean a sale of Common Stock by such Purchaser that is marked as a
non-exempt short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by such Purchaser. For purposes of determining whether there is an equivalent offsetting position in Common Stock held by the
Purchaser, Warrant Shares that have not yet been issued pursuant to the exercise of Warrants shall be deemed to be held long by the Purchaser, and the amount of shares of Common Stock held in a long position shall be all Shares and unexercised
Warrant Shares (ignoring any exercise limitations included therein) issuable to such Purchaser on such date, plus any shares of Common Stock or Common Stock Equivalents otherwise then held by such Purchaser. Notwithstanding the foregoing, in the
event that a Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing
transaction contemplated by this Agreement. Moreover, notwithstanding the foregoing, in the event that a Purchaser has sold Securities pursuant to Rule 144 prior to the Effective Date of the initial Registration Statement and the Company has failed
to deliver certificates book-entry statements without legends prior to the settlement date for such sale (assuming that such certificates or book-entry statements meet the requirements set forth in Section 4.1(c) for the removal of legends),
the provisions of this Section 4.13 shall not prohibit the Purchaser from entering into Net Short Sales for the purpose of delivering shares of Common Stock in settlement of such sale. 

4.14 Delivery of Shares and Warrants After Closing. The Company shall deliver, or cause to be delivered, the respective Shares and
Warrants purchased by each Purchaser to such Purchaser within three Trading Days of the Closing Date. 
 4.15 Participation Rights.
From the date hereof until the date that is 24 months after the Closing Date (the “Participation Period”), the Purchaser listed on Schedule 4.15 (the “Lead Investor”) shall have the right to
participate any unregistered private offerings (in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Act) undertaken by the Company of its Common Stock or Common Stock Equivalents in a financing
transaction (a “Subsequent Financing”) following the Closing Date in an amount up to its Pro Rata Portion, up to a cap of $50 million. At least five Business Days prior to the execution of definitive documentation for a
Subsequent Financing, the Company shall deliver to the Lead Investor a written notice (“Pre-Notice”), which Pre-Notice shall notify the Lead Investor that the Company would like to share with the Lead Investor certain
information which may constitute material non-public information with regard to the Company and which shall ask the Lead Investor if it wants to review such information. The Lead Investor shall have the right, exercisable within two

  
 32 

 
Business Days after its receipt of the Pre-Notice, to notify the Company whether it wishes to review such information. Upon the written request of the Lead Investor, and only upon a request by
such Lead Investor, the Company shall promptly, but no later than one Business Day after receipt of such request, deliver a subsequent notice to the Lead Investor (a “Subsequent Financing Notice”), which Subsequent Financing
Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing. The Lead Investor shall notify the Company by 6:30 p.m. (New York City time) on the second Business Day after its receipt of the Subsequent Financing Notice
of its willingness to participate in the Subsequent Financing on the terms described in the Subsequent Financing Notice. If the Lead Investor fails to timely notify the Company of its willingness to participate in the Subsequent Financing, the
Company may effect such Subsequent Financing without the participation of the Lead Investor on substantially the terms set forth in the Subsequent Financing Notice; provided that the Company must provide the Lead Investor with a second
Subsequent Financing Notice, and the Lead Investor will again have the participation right set forth above in this Section 4.15, if the Subsequent Financing subject to the initial Subsequent Financing Notice is not consummated for any reason on
substantially the terms set forth in such Subsequent Financing Notice within 60 Business Days after the date of the initial Subsequent Financing Notice; provided further, that if the only material change in terms on such second Subsequent
Financing Notice relates to the number of shares to be sold or the price at which such shares are to be sold, then the Lead Investor shall notify the Company by 6:30 p.m. (New York City time) on the first Business Day after its receipt of such
second Subsequent Financing Notice of its willingness to participate in the Subsequent Financing on the revised terms described in such Subsequent Financing Notice. Notwithstanding the foregoing, this Section 4.15 shall not apply in respect of
the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors of the Company pursuant to any stock or option plan (or a bona fide inducement grant to new employees outside of any such plan) duly
adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise of or conversion of
any convertible securities or warrants issued and outstanding on or after the date of or pursuant to this Agreement or any options held by current or former employees or consultants of the Company, (c) shares of Common Stock or securities
convertible into Common Stock issued in connection with acquisitions, asset purchases, licenses, joint ventures, technology license agreements, collaborations or strategic transactions involving the Company and other entities approved by the Board
of Directors, or (d) securities issued to financial institutions or lessors in connection with credit or lending arrangements, equipment financings or lease arrangements. Notwithstanding anything to the contrary herein, this Section 4.15
shall not require the Company to take any action that would require shareholder approval under applicable stock exchange rules or result in a violation of law or stock exchange rule or regulation. 

4.16 Consent to Registered Offerings. Until the expiration of the Participation Period, the Company covenants that it shall not
consummate a primary offering by the Company of securities issued in an offering registered under the Securities Act without the prior written consent of the Lead Investor; provided that such consent shall be deemed to have been granted if:
(i) the Company or its underwriter, placement agent or financial advisor in good faith attempts to inform the Lead Investor of such offering on a confidential basis pursuant to a customary “wall crossing” procedure and the Lead
Investor declines to speak with the Company or its underwriter, placement agent or financial advisor regarding the offering (i.e., it does not come 

  
 33 

 
“over the wall”) (it being understood that the Lead Investor will be deemed to have “declined to speak” to the Company or its underwriter, placement agent or financial
advisor, and thus have given consent to such offering, if it could not be reached or does not provide a response within 48 hours after such good faith attempt to inform the Lead Investor of such offering); or (ii) the Company or its
underwriter, placement agent or financial advisor contacts the Lead Investor following the first public announcement of the public offering and the Lead Investor is offered an allocation of or is allocated in such offering the lesser of:
(A) its requested allocation in such public offering or (B) its Pro Rata Portion, up to a cap of $50 million; or (iii) if the Lead Investor cannot be found or is not responsive during the period between the first public announcement
of the public offering and the pricing of such public offering (which may be the same day as the announcement in the case of a confidentially marketed public offering). Notwithstanding anything to the contrary herein, this Section 4.16 shall
not (1) apply to any offering or sale of securities on Form S-8 or Form S-4, or any similar or successor forms, (2) apply to the filing or effectiveness of any shelf registration statement, whether covering potential sales of Company
securities by the Company or resales of Company securities by selling security holders, (3) apply to offers or sales under any resale registration statement by security holders of the Company, (4) apply to any offering or sale pursuant to
an “at the market” offering by the Company or (5) require the Company to take any action that would require shareholder approval under applicable stock exchange rules or result in a violation of law or stock exchange rule or
regulation. 
 ARTICLE V 

CONDITIONS PRECEDENT TO CLOSING 

5.1 Conditions Precedent to the Obligations of the Purchasers to Purchase Securities. The obligation of each Purchaser to acquire
Shares and Warrants at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by such Purchaser (as to itself only): 

(a) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all
material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made and as of the Closing
Date, as though made on and as of such date, except for such representations and warranties that speak as of a specific date. 
 (b)
Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the
Closing. 
 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. 

(d) Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Securities at the Closing (including all Required Approvals), all of which shall be and remain so long as necessary in full force and effect. 

  
 34 

 (e) Adverse Change. Since the date of execution of this Agreement, no event or series of events
shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect. 
 (f) No Suspensions of Trading in
Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal Trading
Market have been threatened, as of the Closing Date, either (A) in writing by the Commission or the Principal Trading Market or (B) by falling below the minimum listing maintenance requirements of the Principal Trading Market. 

(g) Company Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a). 

(h) Compliance Certificate. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed by its
Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections 5.1(a) and (b) in the form attached hereto as Exhibit G. 

(i) Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with Section 6.18 herein. 

5.2 Conditions Precedent to the Obligations of the Company to sell Securities. The Company’s obligation to sell and issue the
Shares and Warrants at the Closing to the Purchasers is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

(a) Representations and Warranties. The representations and warranties made by the Purchasers in Section 3.2 hereof shall be true and
correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made, and as of
the Closing Date as though made on and as of such date, except for representations and warranties that speak as of a specific date. 
 (b)
Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or
prior to the Closing Date. 
 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been
enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. 

  
 35 

 (d) Consents. The Company shall have obtained in a timely fashion any and all consents, permits,
approvals, registrations and waivers necessary for consummation of the purchase and sale of the Securities at the Closing (including all Required Approvals), all of which shall be and remain so long as necessary in full force and effect. 

(e) Purchasers Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b). 

(f) Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with Section 6.18 herein. 

ARTICLE VI 
 MISCELLANEOUS 

6.1 Fees and Expenses. Except as otherwise expressly set forth in the Company’s engagement letter with the Placement Agent, the
Company and each Purchaser, severally and not jointly with any other Purchaser, shall pay the fees and expenses of their respective advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection
with the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the Securities to the
Purchasers. Each Purchaser, severally and not jointly with any other Purchaser, shall be responsible for all other tax liability that may arise as a result of holding or transferring the Securities by it. Notwithstanding the foregoing, the Company
shall reimburse the Lead Investor for its fees and expenses incurred in connection with the purchase of the Securities and the registration of such Securities under the Registration Rights Agreement, such fees not to exceed $25,000 in the aggregate.

 6.2 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver to the other such further documents as may be reasonably requested in order to give
practical effect to the intention of the parties under the Transaction Documents. 
 6.3 Notices. Any and all notices or other
communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile
(provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this Section 6.3 prior to 5:00 p.m., New York City time, on a Trading Day, (b) the next Trading Day after the
date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 6.3 on a day that is not a Trading Day or later than 5:00 p.m., New York City time, on any Trading Day,
(c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt 

  
 36 

 
by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows: 

 

					
	If to the Company:	  	Pieris Pharmaceuticals, Inc.
		  	255 State Street
		  	Boston, MA 02109
		  	Telephone No.: (857) 246-8998
		  	Facsimile No.: (857) 250-0363
		  	Attention: Chief Financial Officer
	
	With a copy to (which shall not constitute notice):
		
		  	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		  	One Financial Center
		  	Boston, MA 02111
		  	Telephone No.: (617) 542-6000
		  	Facsimile No.: (617) 542-2241
		  	Attention:	  	William C. Hicks, Esq.
		  		  	Marc D. Mantell, Esq.
		
	If to a Purchaser:	  	To the address set forth under such Purchaser’s name on the signature page hereof;

 or such other address as may be designated in writing hereafter, in the same manner, by such Person. 

6.4 Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire a majority of the Shares and the Warrant Shares on a fully-diluted basis at the time of such amendment
(which amendment shall be binding on all Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought). No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any
manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document that, by its terms, applies to all Purchasers,
unless the same consideration is also offered to all Purchasers who then hold Securities. 
 6.5 Construction. The headings herein
are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party
by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents. 

  
 37 

 6.6 Successors and Assigns. The provisions of this Agreement shall inure to the benefit of
and be binding upon the parties and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the written consent of Purchasers holding or having the right to acquire a
majority of the Shares and the Warrant Shares on a fully-diluted basis at the time of such consent except to a successor in the event of a Fundamental Transaction. Any Purchaser may assign its rights hereunder in whole or in part to any Person to
whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and applicable law, provided that such transferee shall agree in writing to be bound, with respect to the transferred Securities, by the terms and
conditions of this Agreement that apply to the “Purchasers”. 
 6.7 No Third-Party Beneficiaries. This Agreement is
intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except (i) the Placement Agent and the
Co-Placement Agents are intended third party beneficiaries of Article III hereof and (ii) each Purchaser Party is an intended third party beneficiary of Section 4.10. 

6.8 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each
party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with
respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such New York Court, or that such
Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY
JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 6.9
Survival. Subject to applicable statute of limitations, the representations, warranties agreements and covenants contained herein shall survive the Closing and the delivery of the Securities. 

6.10 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become 

  
 38 

 
effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission, or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile signature page were an original thereof. 
 6.11 Severability. If any provision of
this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree
upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 

6.12 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and the Transfer Agent for
any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs associated with the issuance of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation thereof, the Company may require delivery of such mutilated
certificate or instrument as a condition precedent to any issuance of a replacement. 
 6.13 Remedies. In addition to being entitled
to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any Action for specific performance of any such obligation (other than in connection with any
Action for a temporary restraining order) the defense that a remedy at law would be adequate. 
 6.14 Payment Set Aside. To the
extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any
part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under
any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. 

  
 39 

 6.15 Adjustments in Share Numbers and Prices. In the event of any stock split,
subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar
recapitalization or event occurring after the date hereof and prior to the Closing, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. 

6.16 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to
purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets,
properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no
Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained herein or in any Transaction
Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its
investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to
independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, Purchasers and their respective
counsels have chosen to communicate with the Company through Goodwin Procter LLP, counsel to the Placement Agent. Each Purchaser acknowledges that Goodwin Procter LLP has rendered legal advice to the Placement Agent and not to such Purchaser in
connection with the transactions contemplated hereby, and that each such Purchaser has relied for such matters on the advice of its own respective counsel. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any Purchaser. 
 6.17 Waiver of
Conflicts. Each Purchaser acknowledges that Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., outside general counsel to the Company, has in the past performed and is or may now or in the future represent one or more Purchasers or their
Affiliates in matters unrelated to the transactions contemplated by the this Agreement, including representation of such Purchasers or their Affiliates in matters of a similar nature to the transactions contemplated by this Agreement. The applicable
rules of professional conduct 

  
 40 

 
require that Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. inform the Purchasers hereunder of this representation and obtain their consent. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C. has served as outside general counsel to the Company and has negotiated the terms of this Agreement solely on behalf of the Company. Each Purchaser hereby (a) acknowledges that they have had an opportunity to ask for and have obtained
information relevant to such representation; (b) acknowledges that with respect to the transactions contemplated by this Agreement, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has represented solely the Company, and not any Purchaser or
any stockholder, director or employee of the Company or any Purchaser; and (c) gives its informed consent to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.’s representation of the Company in the transactions contemplated by this
Agreement. 
 6.18 Termination. This Agreement may be terminated and the sale and purchase of the Shares and the Warrants abandoned
at any time prior to the Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m., New York City time, on the Outside Date;
provided, however, that the right to terminate this Agreement under this Section 6.18 shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure
of the Closing to occur on or before such time. Nothing in this Section 6.18 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents
or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this Section 6.18, the Company shall
promptly notify all non-terminating Purchasers. Upon a termination in accordance with this Section 6.18, the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination)
to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction Documents as a result therefrom. The Company and any Purchaser(s) may extend the term of this Agreement in accordance with the amendment provisions
of Section 6.4 herein. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 41 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

			
	PIERIS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Stephen S. Yoder

	Name:	 	Stephen S. Yoder
	Title:	 	President and Chief Executive Officer

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

[SIGNATURE PAGES FOR PURCHASERS FOLLOW] 

 
			
	NAME OF PURCHASER:	 	 Biotechnology Value Fund, L.P.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$4,306,055.00    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	  

 
			
	         Preferred Stock:
	 	 2,137

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 854,800

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 427,400

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 Biotechnology Value Fund II, L.P.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$2,823,015.00    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	  

 
			
	         Preferred Stock:
	 	 1,401

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 560,400

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 280,200

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 Biotechnology Value Trading Fund OS,
L.P.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$844,285.00    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	  

 
			
	         Preferred Stock:
	 	 419

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 167,600

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 83,800

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 Investment 10, L.L.C.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$695,175.00    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	  

 
			
	         Preferred Stock:
	 	 345

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 138,000

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 69,000

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 MSI BVF SPV, L.L.C.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$1,331,915.00    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	  

 
			
	         Preferred Stock:
	 	 661

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 264,400

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 132,200

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 DAFNA Lifescience LP

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$269,999.93    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 133,995

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 53,598

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 26,799

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 DAFNA Lifescience Select LP

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$179,999.95    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 89,330

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 35,732

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 17,866

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 CVI Investments, Inc. by Heights Capital Management, Inc., its Authorized
Agent

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$999,998.155    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 496,277

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 198,510

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 99,255

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 LINCOLN PARK CAPITAL FUND, LLC
 By: Lincoln
Park Capital LLC
 By: Rockledge Capital Corporation

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$449,999.88    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 223,325

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 89,330

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 44,665

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 1798 FUNDAMENTAL EQUITIES MASTER FUND
LTD.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$999,998.16    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 496,277

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 198,510

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 99,255

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 SABBY HEALTHCARE MASTER FUND, LTD.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$1,999,998.32    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 992,555

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 397,022

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 198,511

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 SABBY VOLATILITY WARRANT MASTER FUND,
LTD.

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$1,000,000.17    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 496,278

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 198,511

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 99,256

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 TEKLA LIFE SCIENCES INVESTORS

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$1,999,999.30    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 59,553

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 23,821

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 11,911

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 TEKLA HEALTHCARE INVESTORS

			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$276,000.60    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 136,973

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 54,790

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 27,394

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 
			
	NAME OF PURCHASER:	 	 TEKLA HEALTHCARE OPPORTUNITIES
FUND

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
	
	Aggregate Purchase Price (Subscription Amount):
	$204,000.62    
	
	Number and Type of Shares to be Acquired:

 
			
		
	         Common Stock:
	 	 101,241

 
			
	         Preferred Stock:
	 	  

 
			
	
	Warrant Shares Subject to:

 
			
		
	
                  Tranche A 
Warrant:
	 	 40,496

	         (40% of the number of Shares to be
acquired)

		
	
                  Tranche B 
Warrant:
	 	 20,248

 
			
	         (20% of the number of Shares to be
acquired)

		
	
                       
     Tax ID No.:
	 	  

 
			
	
	Address for Notice/Residency of Purchaser:
	
	  

	  

	  

		
	Telephone No.:	 	  

		
	Facsimile No.:	 	  

 
			
		
	E-mail Address:	 	  

 
			
		
	Attention:	 	  

  

			
	Delivery Instructions:
	(if different than above)
		
	c/o	 	  

			
	Street:	 	  

			
	City/State/Zip:	 	  

			
	Attention:	 	  

			
	Telephone No.:	 	  

 EXHIBITS: 
  

	A:	Form of Warrant 

	B:	Form of Registration Rights Agreement 

	C-1:	Accredited Investor Questionnaire 

	C-2:	Stock Certificate Questionnaire 

	D:	Form of Opinion of Company Counsel 

	E:	Form of Irrevocable Transfer Agent Instructions 

	F:	Form of Secretary’s Certificate 

	G:	Form of Officer’s Certificate 

	H:	Form of Certificate of Designation 

 EXHIBIT A 

Form of Warrant 

 EXHIBIT B 

Form of Registration Rights Agreement 

 Instruction Sheet 

(to be read in conjunction with the entire Securities Purchase Agreement 

and Registration Rights Agreement) 
  

	A.	Complete the following items in the Securities Purchase Agreement and/or Registration Rights Agreement: 

  

	 	1.	Provide the information regarding the Purchaser requested on the signature page. The Securities Purchase Agreement and the Registration Rights Agreement must be executed by an individual authorized to bind the
Purchaser. 

  

	 	2.	Exhibit C-1 – Accredited Investor Questionnaire: 

 Provide the information requested
by the Accredited Investor Questionnaire 
  

	 	3.	Exhibit C-2 Stock Certificate Questionnaire: 

 Provide the information requested by the
Stock Certificate Questionnaire 
  

	 	4.	Annex B to the Registration Rights Agreement — Selling Securityholder Notice and Questionnaire 

Provide the information requested by the Selling Securityholder Notice and Questionnaire 

 

	 	5.	Return the signed Securities Purchase Agreement and Registration Rights Agreement to: 

 Mariel
Healy 
 Cowen and Company, LLC 

599 Lexington Avenue, 27th Floor 

New York, NY 10022 
 Tel:
(646) 562-1155 
 Fax: (646) 562-1124 

Email: mariel.healy@cowen.com 
  

	B.	Instructions regarding the transfer of funds for the purchase of Securities is set forth below. 

  

			
	 Account Name:
	  	Pieris Pharmaceuticals Inc.
	 Name of Bank:
	  	
	 City/State of Bank:
	  	
	 ACH Routing Number:
	  	
	 Wire Routing Number:
	  	
	 Swift:
	  	
	 Name of Account:
	  	
	 Account Number:
	  	

 EXHIBIT C-1 

ACCREDITED INVESTOR QUESTIONNAIRE 

(ALL INFORMATION WILL BE TREATED CONFIDENTIALLY) 
  

	To:	Pieris Pharmaceuticals, Inc. 

 This Investor Questionnaire (“Questionnaire”) must be completed
by each potential investor in connection with the offer and sale of the shares of the common stock, par value $0.001 per share, certain warrants and shares of common stock that may be issued upon exercise of such warrants (collectively, the
“Securities”), of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Corporation”). The Securities are being offered and sold by the Corporation without registration under the Securities Act of 1933, as
amended (the “Act”), and the securities laws of certain states, in reliance on the exemptions contained in Section 4(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under
applicable state laws. The Corporation must determine that a potential investor meets certain suitability requirements before offering or selling Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each
investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether you meet such criteria, and reliance upon the private offering exemptions from registration is based in part on the
information herein supplied. 
 This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security. Your answers will
be kept strictly confidential. However, by signing this Questionnaire, you will be authorizing the Corporation to provide a completed copy of this Questionnaire to such parties as the Corporation deems appropriate in order to ensure that the offer
and sale of the Securities will not result in a violation of the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of the Securities. All potential investors must answer all
applicable questions and complete, date and sign this Questionnaire. Please print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item. 

 

	PART  A.	BACKGROUND INFORMATION 

  

							
	
Name of Beneficial Owner of the Securities:      
                                         
                                         
                                         
                

	
	
Business Address:               
                                         
                                         
                                         
                                         
        

	(Number and Street)
	
	  

	 (City)
	 	(State)	  		  	(Zip Code)
		
	
Telephone Number: (              
      )
	 	                                 
                                         
                                         
                                         

 If a corporation, partnership, limited liability company, trust or other entity: 

 

							
	Type of entity:
	State of formation:	 	  
	 	Approximate Date of formation:	 	  

 Were you formed for the purpose of investing in the securities being offered? 

Yes
   ̈                    No   ̈ 

If an individual: 
 Residence Address: 

                          
                                  (Number and Street) 

(City)                         
                          (State)              
                                  (Zip Code) 

Telephone Number: (                    ) 

Age:                      Citizenship:
                     Where registered to vote:
                         

Set forth in the space provided below the state(s), if any, in the United States in which you maintained your residence during the past two years and the
dates during which you resided in each state: 
 Are you a director or executive officer of the Corporation? 

Yes    ̈
                     No   ̈ 

Social Security or Taxpayer Identification No. 
  

	PART B.	ACCREDITED INVESTOR QUESTIONNAIRE 

 In order for the Company to offer and sell the
Securities in conformance with state and federal securities laws, the following information must be obtained regarding your investor status. Please initial each category applicable to you as a Purchaser of Securities of the Company. 

 

	 	 ̈  (1)	A bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or
fiduciary capacity; 

  

	 	 ̈  (2)	A broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; 

  

	 	 ̈  (3)	An insurance company as defined in Section 2(13) of the Securities Act; 

  

	 	 ̈  (4)	An investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of such act; 

	 	 ̈  (5)	A Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; 

 

	 	 ̈  (6)	A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in
excess of $5,000,000; 

  

	 	 ̈  (7)	An employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a
bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are
accredited investors; 

  

	 	 ̈  (8)	A private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940; 

  

	 	 ̈  (9)	An organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Securities,
with total assets in excess of $5,000,000; 

  

	 	 ̈  (10)	A trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person who has such knowledge and experience in
financial and business matters that such person is capable of evaluating the merits and risks of investing in the Company; 

  

	 	 ̈  (11)	A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 (excluding the value of such persons’ primary residence);

  

	 	 ̈  (12)	A natural person who had an individual income in excess of $200,000 in each of the two most recent years, or joint income with that person’s spouse in excess of $300,000, in each of those years, and has a
reasonable expectation of reaching the same income level in the current year; 

  

	 	 ̈  (13)	An executive officer or director of the Company; 

  

	 	 ̈  (14)	An entity in which all of the equity owners qualify under any of the above subparagraphs. If the undersigned belongs to this investor category only, list the equity owners of the undersigned, and the investor category
which each such equity owner satisfies. 

							
	 A.     FOR EXECUTION BY AN INDIVIDUAL:

 
	 	
	
Date                    
	 		 	By	 	  

		 		 	Print Name:	 	  

				
	 B.     FOR EXECUTION BY AN ENTITY:
	 		 		 	
				
		 		 	Entity Name:	 	  

				
	
Date                    
	 		 	By	 	  

		 		 	Print Name:	 	  

		 		 	Title:	 	  

	
	 C.     ADDITIONAL SIGNATURES (if required by
partnership, corporation or trust document):

				
		 		 	Entity Name:	 	  

				
	
Date                    
	 		 	By	 	  

		 		 	Print Name:	 	  

		 		 	Title:	 	  

				
		 		 	Entity Name:	 	  

				
	
Date                    
	 		 	By	 	  

		 		 	Print Name:	 	  

		 		 	Title:	 	  

 EXHIBIT C-2 

Stock Certificate Questionnaire 
 Pursuant to
Section 2.2(b) of the Agreement, please provide us with the following information: 
 1. The exact name that the Securities are to be registered in
(this is the name that will appear on the stock certificate(s)). You may use a nominee name if appropriate: 
 2. The relationship between the Purchaser of
the Securities and the Registered Holder listed in response to Item 1 above: 
 3. The mailing address, telephone and telecopy number of the Registered
Holder listed in response to Item 1 above: 
 4. The Tax Identification Number (or, if an individual, the Social Security Number) of the Registered
Holder listed in response to Item 1 above: 

 EXHIBIT D-1 

Form of Opinion of Company Counsel 

1. The Company is qualified to conduct business as a foreign corporation in the Commonwealth of Massachusetts. 

2. Each of the Transaction Documents constitutes the valid and binding agreement of the Company, enforceable against the Company in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights generally, and subject to general
equity principles and to limitations on availability of equitable relief, including specific performance. 
 3. The execution, delivery and
performance of the Transaction Documents by the Company, the compliance with the terms and provisions thereof by the Company and the issuance and sale of the Securities by the Company will not (a) violate or conflict with any law, rule or
regulation of the United States of America, the Commonwealth of Massachusetts or the State of New York that in our experience is normally applicable to transactions of the type contemplated by the Transaction Documents or (b) violate any
agreement to which the Company is a party or bound (this opinion being limited (i) to those agreements identified on Exhibit A attached hereto (the “Material Contracts”) and (ii) in that we express no opinion with
respect to any violation or default (A) arising under or based upon any cross- default provision insofar as it relates to a violation or default under an agreement not identified on Exhibit A attached hereto, (B) arising as a result
of any violation or default under any agreement or covenant by failure to comply with any financial or numerical requirement requiring computation or (C) under any provisions therein relating to the occurrence of a “material adverse
event” or words of similar import). 
 4. No consent, approval, authorization or order of, or filing with, any governmental agency or
body or any court is required in connection with the execution, delivery or performance of the Transaction Documents by the Company, or in connection with the issuance or sale of the Securities by the Company to the Purchasers, except (i) the
filing with the Securities and Exchange Commission of one or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, (ii) filings required by applicable state securities laws, (iii) the filing
of a Notice of Sale of Securities on Form D with the Securities and Exchange Commission under Regulation D of the Securities Act of 1933, as amended, (iv) the filing of any requisite notices and/or application(s) to the Nasdaq Capital Market
for the issuance and sale of the Securities and the listing of the Shares and Warrant Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with
Section 4.6 of the Purchase Agreement and (vi) those that have been made or obtained prior to the date hereof. 
 5. It is not
necessary in connection with the offer and sale of the Securities to the Purchasers under the Purchase Agreement to register the Securities under the Securities Act of 1933, as amended, assuming the accuracy of the representations and warranties of
the Purchasers in the Purchase Agreement. 

 6. To our actual knowledge, there is no litigation or any governmental proceeding involving the
Company, pending or threatened, that challenges the validity or enforceability of the Purchase Agreement or the Registration Rights Agreement, or seeks to enjoin the performance of the Purchase Agreement or the Registration Rights Agreement by the
Company. 
 7. The Company is not required to register as an “investment company,” as such term is defined in the Investment
Company Act of 1940, as amended. 

 EXHIBIT D-2 

Form of Opinion of Nevada Counsel 

1. The Company is validly existing as a corporation and in good standing under the laws of the State of Nevada, with the corporate power and
authority to (a) execute and deliver the Transaction Documents and perform its obligations thereunder and (b) to conduct its business and own or lease its properties as described in the Company’s Annual Report on Form 10-K for the
year ending December 31, 2015, as filed with the Securities and Exchange Commission on March 23, 2016 (but not any document incorporated by reference therein). 

2. The execution and delivery by the Company of the Transaction Documents, the performance by the Company of its obligations thereunder and
the consummation of the Transactions have been duly authorized by the Company. 
 3. The Company has duly executed and delivered each of the
Transaction Documents. 
 4. The execution and delivery by the Company of the Transaction Documents and the consummation of the Transactions
(including the issuance and sale by the Company of the Securities pursuant to and in accordance with the Transaction Documents) do not violate the Governing Documents or any Applicable Nevada Law. 

5. As of the date hereof, the authorized capital stock of the Company consists of 300,000,000 shares of common stock, par value $0.001 per
share, and 10,000,000 shares of preferred stock, par value $0.001 per share. 
 6. The Common Shares have been duly authorized by the
Company and, when and to the extent issued and sold in accordance with the terms of, and in the manner contemplated by, the Purchase Agreement, including payment in full to the Company of all consideration required therefor, the Common Shares will
be validly issued, fully paid and non-assessable. 
 7. The Conversion Shares have been duly authorized by the Company and, if, when and to
the extent issued in accordance with the terms of, and in the manner contemplated by, the Purchase Agreement and the certificate of designation for the Preferred Stock, including the due and proper conversion of the relevant Preferred Shares and
payment in full to the Company of any consideration for the Conversion Shares as required therefor, the Conversion Shares will be validly issued, fully paid and non-assessable. 

8. The Warrant Shares have been duly authorized by the Company and, if, when and to the extent issued in accordance with the terms of, and in
the manner contemplated by, the Purchase Agreement and the Warrants, including the due and proper exercise of the Warrants and payment in full to the Company of the exercise price and any other consideration for the Warrant Shares as required
therefor, the Warrant Shares will be validly issued, fully paid and non-assessable. 
 9. As of the date hereof, the holders of shares of
Common Stock are not entitled to preemptive rights arising solely by operation of (a) the NRS or (b) the Governing Documents. 

 10. No consent, approval, authorization, order, registration or qualification of, from or with
any Nevada Governmental Authority is required to be obtained by the Company under Applicable Nevada Law for the execution and delivery by the Company of the Transaction Documents or the consummation of the Transactions, except (a) those
obtained or made prior to the date hereof and that are in full force and effect, and (b) such as are permitted by the Transaction Documents to be obtained or made after the closing of the Transactions. 

 EXHIBIT E 

Irrevocable Transfer Agent Instructions 

As of June 8, 2016 
 Computershare Trust
Company, N.A. 
 P.O. Box 30170 
 College Station,
TX 77842-3170 
 Attn:                     
                     
 Ladies and Gentlemen: 

Reference is made to that certain Securities Purchase Agreement, dated as of June 2, 2016 (the “Agreement”), by
and among Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the purchasers named on the signature pages thereto (collectively, and including permitted transferees, the “Holders”),
pursuant to which the Company is issuing to the Holders shares (the “Shares”) of Common Stock of the Company, par value $0.001 per share (the “Common Stock”), and warrants (the
“Warrants”), which are exercisable into shares of Common Stock (the “Warrant Shares”). 

This letter shall serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such
time and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you from time to time, if any, to issue certificates representing shares of Common Stock upon transfer or resale of the
Shares or Warrant Shares. 
 You acknowledge and agree that so long as you have received written confirmation from the Company’s legal
counsel that a registration statement covering resales of the Shares and the Warrant Shares has been declared effective by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended
(the “Securities Act”), and a copy of such registration statement, then, unless otherwise required by law, you shall use your commercially reasonable efforts to issue the certificates representing the Shares or Warrant Shares
registered in the names of such Holders or transferees, as the case may be, within three Business Days of your receipt of a notice of transfer of Shares or Warrant Shares, and such certificates shall not bear any legend restricting transfer of the
Shares or Warrant Shares thereby and should not be subject to any stop-transfer restriction. 
 A form of written confirmation from the
Company’s outside legal counsel that a registration statement covering resales of the Shares and the Warrant Shares has been declared effective by the Commission under the Securities Act (which confirmation shall be delivered to you upon
effectiveness of the registration statement) is attached hereto as Annex I. 

 Please be advised that the Holders are relying upon this letter as an inducement to enter into
the Agreement and, accordingly, each Holder is a third party beneficiary to these instructions. 
 Please execute this letter in the space
indicated to acknowledge your agreement to act in accordance with these instructions. 
 [Signature page follows] 

 

			
	Very truly yours,
	
	PIERIS PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Title :	 	  

  

			
	Acknowledged and Agreed:
	
	COMPUTERSHARE TRUST COMPANY, N.A.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	Date:              , 2016

 Annex I 

FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION STATEMENT 

Computershare Trust Company, N.A. 
 P.O. Box 30170 

College Station, TX 77842-3170 
 Attn:
                                         

 Re: Pieris Pharmaceuticals, Inc. 

Ladies and Gentlemen: 
 Pieris Pharmaceuticals,
Inc., a Nevada corporation (the “Company”), has entered into a Securities Purchase Agreement, dated as of June 2, 2016, with the buyers named therein (collectively, the “Purchasers”) pursuant to
which the Company issued to the Purchasers shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and warrants exercisable for shares of Common Stock (the
“Warrants”). Pursuant to that certain Registration Rights Agreement of even date, the Company agreed to register the resale of the Common Stock, including the shares of Common Stock issuable upon exercise of the Warrants
(collectively, the “Registrable Securities”), under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the Company’s obligations under the Registration Rights
Agreement, on              ,         , the Company filed a Registration Statement on Form S-1 (File
No. 333-            ) (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) relating to
the Registrable Securities which names each of the Purchasers as a selling stockholder thereunder and set forth as Exhibit A hereto. 

In connection with the foregoing, we advise you that a member of the Commission’s staff has advised us by telephone that the Commission
has entered an order declaring the Registration Statement effective under the Securities Act at          [a.m.][p.m.] on             ,
        , and we have no knowledge, after telephonic inquiry of a member of the staff, that any stop order suspending its effectiveness has been issued or that any proceedings for that purpose are
pending before, or threatened by, the Commission and the Registrable Securities are available for resale under the Securities Act pursuant to the Registration Statement. Based upon the foregoing, we are of the opinion that as of the date of this
opinion, the Registrable Securities have been duly authorized and, when issued by you, will be validly issued, fully paid and non-assessable, and are registered for resale under the Securities Act under the effective Registration Statement and may
be issued without a restrictive legend. 
 This letter shall serve as our standing notice to you that the Common Stock may be freely
transferred by the Purchasers pursuant to the Registration Statement. You need not require further letters from us to effect any future legend-free issuance or reissuance of shares of Common Stock to the Purchasers or the transferees of the
Purchasers, as the case may be, as contemplated by the Company’s Irrevocable Transfer Agent Instructions dated June 8, 2016, provided at the time of such reissuance, the Company has not otherwise notified you that the Registration
Statement is unavailable for the resale of the Registrable Securities. This letter shall serve as our standing instructions with regard to this matter. 

 [Signature page follows] 

 

			
	Very truly yours,
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 EXHIBIT F 

Form of Secretary’s Certificate 

The undersigned hereby certifies that he is the duly elected, qualified and acting Secretary of Pieris Pharmaceuticals, Inc., a Nevada
corporation (the “Company”), and that as such he is authorized to execute and deliver this certificate in the name and on behalf of the Company and in connection with the Securities Purchase Agreement, dated as of
June 2, 2016, by and among the Company and the investors party thereto (the “Securities Purchase Agreement”), and further certifies in his official capacity, in the name and on behalf of the Company, the items set forth
below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase Agreement. 
 (a)
Attached hereto as Exhibit A is a true, correct and complete copy of the resolutions duly adopted by the Board of Directors of the Company (the “Board”) by unanimous written consent on
[            ,         ] approving the transactions contemplated by the Securities Purchase Agreement and the other Transaction
Documents and the issuance of the Securities. Such resolutions have not in any way been amended, modified, revoked or rescinded, have been in full force and effect since their adoption to and including the date hereof and are now in full force and
effect. 
 (b) Attached hereto as Exhibit B is a true, correct and complete copy of the Articles of Incorporation of the Company,
together with any and all amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Articles of Incorporation, the same being in full force and effect in the attached form as of the date hereof.

 (c) Attached hereto as Exhibit C is a true, correct and complete copy of the Bylaws of the Company and any and all amendments
thereto currently in effect, and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect in the attached form as of the date hereof. 

(d) Each person listed below has been duly elected or appointed to the position(s) indicated opposite his name and is duly authorized to sign
the Securities Purchase Agreement and each of the Transaction Documents on behalf of the Company, and the signature appearing opposite such person’s name below is such person’s genuine signature. 

 

					
	 Name
	  	 Position
	 	 Signature

			
		  	[                    ]	 	Chief Executive Officer
			
		  		 	  

			
		  	[                    ]	 	Chief Financial Officer
			
		  		 	  

 IN WITNESS WHEREOF, the undersigned has hereunto set his hand as of this      day of
June, 2016. 
  

	
	[Name]
	Secretary

 I, [Name], Chief Financial Officer, hereby certify that [Name] is the duly elected, qualified and acting Secretary of
the Company and that the signature set forth above is his true signature. 
  

	
	  

	[Name]
	Chief Financial Officer

 EXHIBIT A 

Resolutions 
 EXHIBIT B 

Articles of Incorporation 
 EXHIBIT C 

Bylaws 

 EXHIBIT G 

Form of Officer’s Certificate 
 The
undersigned, the Chief Executive Officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), pursuant to Section 5.1(h) of the Securities Purchase Agreement, dated as of June 2, 2016, by and among
the Company and the investors signatory thereto (the “Securities Purchase Agreement”), hereby represents, warrants and certifies as follows (capitalized terms used but not otherwise defined herein shall have the meaning set
forth in the Securities Purchase Agreement): 
  

	 	1.	The representations and warranties of the Company contained in the Securities Purchase Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as to
materiality, in which case, such representations and warranties shall be true and correct in all respects) as of the date when made and as of the date hereof, as though made on and as of such date, except for such representations and warranties that
speak as of a specific date. 

  

	 	2.	The Company has performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or
prior to the date hereof. 

 IN WITNESS WHEREOF, the undersigned has executed this certificate this
     day of June, 2016 
  

	
	  

	Steven S. Yoder
	Chief Executive Officer

 EXHIBIT H 

Form of Certificate of Designation 

 Schedule 4.15 

Lead Investor 
  

Biotechnology Value Fund, L.P. 
 Biotechnology Value Fund II,
L.P. 
 Biotechnology Value Trading Fund OS, L.P. 
 Investment
10, L.L.C. 
 MSA BVF SPV, L.L.C.EX-10.2

 Exhibit 10.2 

NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE
SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. 

PIERIS PHARMACEUTICALS, INC. 

WARRANT TO PURCHASE COMMON STOCK 

Original Issue Date: June     , 2016 

Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby certifies that, for value received,
                     or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up
to a total of                      shares of common stock, $0.001 par value per share (the “Common Stock”), of the
Company (the “Warrant Shares”) at an exercise price per share equal to $        1 per share (as adjusted from time to time as
provided in Section 9 herein, the “Exercise Price”), at any time and from time to time on or after the date hereof (the “Original Issue Date”) and through and including 5:30 p.m., New York City
time, on June 8, 2021 (the “Expiration Date”), and subject to the following terms and conditions: 
 This Warrant (this
“Warrant”) is one of a series of similar tranche of warrants issued pursuant to that certain Securities Purchase Agreement, dated June 2, 2016, by and among the Company and the Purchasers identified therein (the
“Purchase Agreement”). All such Warrants are referred to herein, collectively, as the “Warrants.” 
 1.
Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement. 

2. Registration of Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose, which may be a
third-party transfer agent (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned
hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary. 
  
  

	1 	To be $2.00 per share for Tranche A Warrants and $3.00 per share for Tranche B Warrants. 

 3. Registration of Transfers. Subject to the restrictions on transfer set forth in Section 4.1 of the
Purchase Agreement and compliance with all applicable securities laws, the Company shall register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached as
Schedule 2 hereto duly completed and signed, to the Company’s transfer agent or to the Company at its address specified in the Purchase Agreement and (x) delivery, at the request of the Company, of an opinion of counsel reasonably
satisfactory to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state securities or blue sky laws
(other than in connection with any transfer (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144), and (y) delivery by the transferee of a written statement to the Company
certifying that the transferee is an “accredited investor” as defined in Rule 501(a) under the Securities Act and making the representations and certifications set forth in Sections 3.2(c), (d), (f), (j) and (m) of the Purchase
Agreement, to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “New
Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring
Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company
shall prepare, issue and deliver at its own expense any New Warrant under this Section 3. 
 4. Exercise and Duration of Warrant. 

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by Section 10 of this Warrant at
any time and from time to time on or after the Original Issue Date and through and including 5:30 p.m. New York City time, on the Expiration Date. At 5:30 p.m., New York City time, on the Expiration Date, the portion (or all) of this Warrant not
exercised prior thereto shall be and become void and of no value and this Warrant shall be automatically terminated and no longer outstanding, provided, however, that if the last reported Closing Sale Price immediately prior to the Expiration
Date was greater than the Exercise Price, then this Warrant shall be automatically deemed exercise on a cashless basis as of 4:01 p.m. (ET) on the Expiration Date. 

(b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1
hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless
exercise” if so indicated in the Exercise Notice and if a “cashless exercise” may occur at such time pursuant to Section 10 below), and the date on which Exercise Notice is delivered to the Company (as determined in accordance
with the notice provisions hereof) is an “Exercise Date.” The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above shall constitute the Holder’s
certification to the Company that its representations contained in Sections 3.2(b), (c), (d), (f), (j) and (m) of the Purchase Agreement are true and correct as of the Exercise Date and the date on which Holder pays the Company the
Exercise Price as if remade in their entirety (or, in the case of any transferee Holder that is not a party to 

  
 2 

 
the Purchase Agreement, such transferee Holder’s certification to the Company that such representations are true and correct as to such assignee Holder as of the Exercise Date). The Holder
shall not be required to deliver the original Warrant in order to effect an exercise hereunder, but if it is not so delivered then such exercise shall constitute an agreement by the Holder to deliver the original Warrant to the Company as soon as
practicable thereafter. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares. 

5. Delivery of Warrant Shares. 
 (a) Upon
exercise of this Warrant and delivery of the Exercise Price, the Company shall promptly (but in no event later than three Trading Days after the later of the Exercise Date and delivery of the Exercise Price) issue or cause to be issued and cause to
be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate (provided that, if the Registration Statement is not effective and the Holder directs the Company to deliver a certificate for the Warrant
Shares in a name other than that of the Holder or an Affiliate of the Holder, it shall deliver to the Company on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect that the issuance of such Warrant Shares in
such other name may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state securities or blue sky laws), (i) a certificate for the Warrant Shares issuable upon such exercise,
free of restrictive legends, or (ii) an electronic delivery of the Warrant Shares to the Holder’s account at the Depository Trust Company (“DTC”) or a similar organization, unless in the case of clause (i) and
(ii) a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the Warrant Shares are not freely transferable without restriction under Rule 144 by
Holders who are not affiliates of the Company, in which case such Holder shall receive a certificate for the Warrant Shares issuable upon such exercise with appropriate restrictive legends. The Holder, or any Person permissibly so designated by the
Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. Notwithstanding anything contained herein to the contrary, if the Holder fails to deliver the documents required to
register a transferee as set forth in Section 3 above or to provide the documents required under this Section 5(a) to issue a certificate or electronic delivery of the Warrant Shares to any Person(s) other than the Holder, then
determination of the three Trading Days shall be tolled until such documents have been delivered to the Company. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon the written request of the Holder, use
its reasonable best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through DTC or another established clearing corporation performing similar functions, if available; provided, that, the Company may, but will
not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically through such a clearing corporation. “Trading Day” means any day on which the Common Stock are traded on
the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided that
“Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock are suspended from trading during the final hour of
trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time). 

  
 3 

 (b) If by the close of the third Trading Day after delivery of a properly completed
Exercise Notice and the payment of the aggregate Exercise Price in any manner permitted by Section 10 of this Warrant, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner
required pursuant to Section 5(a), and if after such third Trading Day and prior to the receipt of such Warrant Shares, the Holder is required to purchase (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall, in its sole discretion, within three Trading Days after the
Holder’s request for payment, either (1) pay in cash to the Holder an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the number
of Warrant Shares underlying this Warrant equal to the number of shares of Common Stock so purchased shall be forfeited and the Company’s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate or
(2) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the product of (A) the number of shares of Common Stock purchased in the Buy-In, multiplied by (B) the closing bid price of a share of Common
Stock on the Exercise Date. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by the Company.

 (c) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject
to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company
(other than breaches related to this Warrant or the Purchase Agreement) or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the
Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 

6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without
charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the 

  
 4 

 
Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this
Warrant or receiving Warrant Shares upon exercise hereof. 
 7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such
loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company
as a condition precedent to the Company’s obligation to issue the New Warrant. 
 8. Reservation of Warrant Shares. The Company represents and
warrants that on the date hereof, it has duly authorized and reserved, and covenants that it will at all times during the period this Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire
Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and
deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the original issuance thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company represents and warrants that the
Warrant Shares, when issued and paid for in accordance with the terms of the Transaction Documents and the Warrants, will be issued free and clear of all security interests, claims, liens and other encumbrances other than restrictions imposed by
applicable securities laws. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any
requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. 
 9. Certain Adjustments. The
Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9. 

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its
Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares, (iii) combines (by

  
 5 

 
combination, reverse stock split or otherwise) its outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of Common Stock any shares
of capital stock of the Company, then in each such case the Exercise Price shall be adjusted to a price determined by multiplying the Exercise Price in effect immediately prior to the effective date of such event by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding on such effective date immediately before giving effect to such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after giving
effect to such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any
adjustment pursuant to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately after the effective date of such subdivision, combination or reclassification. 

(b) Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock
for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii) rights or warrants to subscribe for or purchase any security, or
(iv) any other asset, including cash (in each case, “Distributed Property”), except, in the case of subsections (b)(i) through (b)(iv) hereof, for any distributions pursuant to a shareholders’ rights plan or similar
takeover defense agreement or plan adopted by the Company, then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to
receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the
record holder of such Warrant Shares immediately prior to such record date. 
 (c) Fundamental Transactions. If, at any time while
this Warrant is outstanding (i) the Company effects (A) any merger of the Company with (but not into) another Person, in which stockholders of the Company immediately prior to such transaction own less than a majority of the outstanding
stock of the surviving entity, or (B) any merger or consolidation of the Company into another Person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any
tender offer or exchange offer approved or authorized by the Company’s Board of Directors is completed pursuant to which holders of at least a majority of the outstanding Common Stock tender or exchange their shares for other securities, cash
or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than
as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above or as a result of a transaction, the primary purpose of which is to change the jurisdiction of incorporation of the Company) (in any such case,
a “Fundamental Transaction”), then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon
the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on
exercise contained herein (the “Alternate Consideration”), and the Holder shall no longer have the right to receive 

  
 6 

 
Warrant Shares upon exercise of this Warrant. The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof, any successor to the
Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or Person shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the
foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions of an analogous type to any Fundamental
Transaction. 
 (d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph
(a) of this Section 9, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the
increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. 

(e) Calculations. All calculations under this Section 9 shall be made to the nearest cent or the nearest share, as applicable.

 (f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will
promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares
or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in reasonable detail the facts upon which such adjustment is based. The Company will promptly deliver
a copy of each such certificate to the Holder and to the Company’s transfer agent. 
 (g) Notice of Corporate Events. If, while
this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for
or purchase any capital stock of the Company, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation
or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten
(10) Trading Days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such
notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. 
 10. Payment of Exercise
Price. The Holder shall either pay the Exercise Price in immediately available funds or by way of a “cashless exercise”, in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: 

X = Y [(A-B)/A] 

  
 7 

 where: 

X = the number of Warrant Shares to be issued to the Holder. 

Y = the total number of Warrant Shares with respect to which this Warrant is being exercised. 

A = the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg Financial Markets) for the five consecutive
Trading Days ending on the date immediately preceding the Exercise Date. 
 B = the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise. 
 For purposes of this Warrant, “Closing Sale Price” means, for any security as of any date,
the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate a last
trade price, then the last trade price of such security prior to 4:00 p.m., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last closing price of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if no closing bid price is reported for such security by Bloomberg Financial Markets, the average of the bid prices of any market makers for such
security as reported in the “pink sheets” by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be
the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment
to determine the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable calculation period. 
 For purposes of Rule 144, it is intended, understood and acknowledged
that the provisions above permitting “cashless exercise” are intended, in part, to ensure that a full or partial exchange of this Warrant pursuant to such provisions will qualify as a conversion, within the meaning of paragraph (d)(3)(ii)
of Rule 144, and the holding period for the Warrant Shares shall be deemed to have commenced as to such original Holder, on the Original Issue Date. 
 11.
Limitations on Exercise. Notwithstanding anything to the contrary contained herein, the number of Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the
extent necessary to ensure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by the Holder (together with such Holder’s Affiliates, and any other Person whose beneficial
ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act and the applicable regulations of the Commission, including any “group” of which the Holder is a member) does not
exceed [9.99][4.99]% of the total 

  
 8 

 
number of then issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise) (the “Beneficial Ownership
Limit”). For such purposes, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is
not representing to such Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and such Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
Beneficial Ownership Limit applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which a portion of this Warrant is exercisable shall be in the sole discretion of a Holder,
and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable, in
each case subject to the Beneficial Ownership Limit, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 11, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or the
Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three Trading Days confirm orally and in writing to such Holder the number of shares of Common Stock then
outstanding. This provision shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a
Fundamental Transaction as contemplated in Section 9 of this Warrant. By written notice to the Company, the Holder may increase or decrease the Beneficial Ownership Limit applicable solely to such Holder to such other percentage limit as may be
determined by the Holder, not to exceed [19.99][9.99]%, provided that any increase in the Beneficial Ownership Limit shall not be effective until the 61st day after such notice is delivered to the
Company. 
 12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any
such fractional shares. 
 13. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any
Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in the Purchase Agreement
prior to 5:30 p.m., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in the Purchase Agreement on a day
that is not a Trading Day or later than 5:30 p.m., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or

  
 9 

 
(iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The address and facsimile number of a Person for such notices or communications shall be
as set forth in the Purchase Agreement unless changed by such Person by two Trading Days’ prior notice to the other Person(s) in accordance with this Section 13. 

14. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon 15 days’ notice to the Holder, the Company may appoint a new
warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company
or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice
of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register. 

15. Miscellaneous. 
 (a) No Rights as a
Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities,
whether such liabilities are asserted by the Company or by creditors of the Company. 
 (b) Authorized Shares. 

(i) The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation or of any requirements of the Trading Market upon which the Common Stock may be listed. 

(ii) Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(b) take all such action as may be necessary or appropriate in order that the Company may 

  
 10 

 
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. 

(iii) Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 

(c) Successors and Assigns. Subject to the restrictions on transfer set forth in this Warrant and in Section 4.1 of the Purchase
Agreement, and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person
other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. 
 (d) Amendment and
Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Holders of Warrants representing no less than a majority of the Warrant Shares obtainable upon exercise of the Warrants then outstanding. 

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. 
 (f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR
DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) 

  
 11 

 
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THE PURCHASE AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.
NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. 

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. 
 (h) Severability. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which as closely as possible reflects the intent of the parties hereto, and upon so agreeing, shall incorporate such substitute provision in this Warrant. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK, 

SIGNATURE PAGE FOLLOWS] 
 IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above. 
  

			
	PIERIS PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 12 

 SCHEDULE 1 

PIERIS PHARMACEUTICALS, INC. 

FORM OF EXERCISE NOTICE 
 [To be
executed by the Holder to purchase shares of Common Stock under the Warrant] 
 Ladies and Gentlemen: 

(1) The undersigned is the Holder of Warrant No.
                     (the “Warrant”) issued by Pieris Pharmaceuticals, Inc., a Nevada corporation (the
“Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. 

(2) The undersigned hereby exercises its right to purchase
                 Warrant Shares pursuant to the Warrant. 
 (3) The
Holder intends that payment of the Exercise Price shall be made as (check one): 
  

	 	 ̈	Cash Exercise 

  

	 	 ̈	“Cashless Exercise” under Section 10 of the Warrant 

 (4) If the Holder has elected a Cash
Exercise, the Holder shall pay the sum of $             in immediately available funds to the Company in accordance with the terms of the Warrant. 

(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. Please
issue (check applicable box): 
  

	 	 ̈	A certificate of certificates representing the Holder Warrant Shares in the name of the undersigned or in such other name as is specified below: 

 

                       
                                         
                                         
                                         
                                       

 

	 	 ̈	The Holder Warrant Shares in electronic form to the following account: 

  

			
	   Name and Contact for Broker:	 	  

			
	   Broker no:	 	  

			
	   Account no:	 	  

			
	   Account holder:	  	  

 (6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to
the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with 

  
 13 

 
Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11 of the Warrant to which this notice relates. 

Dated:             ,          

 

			
	Name of Holder:	 	  

			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 (Signature must conform in all respects to name of Holder as specified on the face of the Warrant) 

  
 14 

 SCHEDULE 2 

PIERIS PHARMACEUTICALS, INC. 

FORM OF ASSIGNMENT 
 [To be
completed and executed by the Holder only upon transfer of the Warrant] 
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
                     (the “Transferee”) the right represented by the within Warrant to purchase
                 shares of Common Stock of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”) to which the within Warrant
relates and appoints                      attorney to transfer said right on the books of the Company with full power of substitution in the
premises. In connection therewith, the undersigned represents, warrants, covenants and agrees to and with the Company that: 
  

	(a)	the offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4(1) of the United States Securities Act of 1933, as amended (the “Securities Act”), or another
valid exemption from the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States; 

 

	(b)	the undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not limited to, any advertisement, article, notice or other communication published in any
newspaper, magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; 

 

	(c)	the undersigned has read the Transferee’s investment letter included herewith, and to its actual knowledge, the statements made therein are true and correct; and 

 

	(d)	the undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion
of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable securities
laws of the states of the United States. 

  

					
	Dated:                     	 		 	
			
		 		 	  

		 		 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
			
		 		 	  

			
		 		 	Address of Transferee
			
	In the presence of:	 		 	  

			
	  
	 		 	  

  
 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]